

## Index

- a**
- ABC (ATP-binding cassette) 35
- absorption 209
- absorption, distribution,  
metabolization, excretion,  
and toxicity (ADME-T) 306
- academic excellence meets  
entrepreneurship 450
- acetone 393
- N*-acetylglucosamine 9, 12, 91–92
- acetylsalicylic acid 15, 317
- acrylamide 108, 396
- actin filaments(F actin) 50–53, 261
- action potential 35, 37, 92, 183, 372
- activated executioner caspases 60,  
61, 254
- activation energy 22
- activation of transcription factors  
188
- active cell recognition 313
- active (native) conformation 107
- active targeting 311, 313, 315
- active transport 35, 36, 43, 247, 318
- acyclovir 313, 317
- Ad5 virus 167
- adapter proteins 38, 92, 371
- adaptor sequences 152
- adenine 25, 72, 73, 75, 80, 83, 84,  
137, 270, 283, 403, 409
- adeno-associated virus (AAV) 179,  
369, 417, 418
- adenosine 24, 25, 69, 72, 84, 89,  
152, 223, 231, 240, 326, 327,  
410, 418
- adenosine deaminase deficiency  
326
- adenosine triphosphate (ATP)  
24–26, 35–38, 40, 43, 45–48,  
50–52, 69, 71, 84, 89, 114,  
142, 144, 154, 180, 211, 240,  
243, 248
- adenoviral expression systems 167
- adenyl cyclase 37, 38, 41, 55
- adsorption chromatography 133
- adsorptive interactions 109
- advanced breast carcinomas 313
- adverse drug reactions (ADRs) 421
- affine gap cost model 281
- affinity chromatography 113, 124,  
130, 133, 164, 172, 346, 349
- affinity purification/mass  
spectrometry (AP-MS) 123
- Affymetrix GeneChip<sup>®</sup> 139
- agarose gel 134, 138, 149, 271
- agarose gel electrophoresis 134
- aggregation chimeric mice 366
- aging process 68
- agouti 365
- agricultural biotechnology 384,  
385, 449
- agriculture and food production  
422
- agronomic characteristics 376
- alcohol oxidase 1 (AOX1) 164, 176
- alcohol oxidase gene 164
- alcoholic drinks 393
- alcoholic fermentation 413, 445
- aldosterone 16, 17
- algae 3, 46, 48, 57, 95, 97, 125, 134,  
378, 385, 406
- alkyltransferases 73
- allele frequencies of somatic variants  
292
- allosteric ligands 24
- alpha-amino-3-hydroxyl-5-methyl-4-  
isoxazol-propionate (AMPA)  
371
- alpha-factor 190–191
- $\alpha$ -purple bacteria 45, 47
- alternatively spliced mRNAs 75
- Alu 67
- Alveolata 3
- Amgen Genentech 450
- Amido black 108
- amino acid(s) 3, 9, 14, 17–22, 29,  
34, 42, 45, 47, 50, 55, 63,  
74–75, 81, 83–84, 87, 89,  
107–108, 111–112, 119, 122,  
167, 172, 176, 180, 205–206,  
221, 240, 244–245, 261,  
263–264, 266–267, 270, 278,  
280–281, 283–285, 302,  
326–329, 352, 354, 376, 378,  
395–397, 399, 403–404,  
407–409, 441, 446
- D-amino acids 18
- L-amino acids 18
- composition 263, 281
- amino-/N-terminal 17
- aminoacyl-tRNAs 83
- 5-aminosalicylic acid 319
- ammonium sulfate 109, 114
- Ampakines 371
- AmpC 55
- amphipathic helices 280
- amphiphilic molecules 14
- ampholytes 108
- amphotropic retroviruses 168
- ampicillin 115, 159, 162, 163, 178,  
317
- ampicillin resistance 159, 163,  
178
- gene 159, 163
- amplicon 147–149, 151, 155,  
333–335
- amplification(s) 37, 66–67,  
147–151, 153, 155–157,  
159–162, 168, 177–178, 201,  
210, 218–219, 225, 292,  
327–333, 335–337, 365, 421
- amplification refractory mutation  
system (ARMS) 336

- amplification-created restriction sites (ACRS) 336  
 AMV reverse transcriptase 144  
 amylose 10  
 amyotrophic lateral sclerosis (ALS) 370–371  
 anabolism 49, 50  
 analyzer 117, 118, 202  
 anaphase 69, 70, 188, 189  
 anaphase I 70  
 anaphase II 70  
 anchor proteins 36  
 androgens 17  
 Andromeda 121, 125  
 animal and plant tissues 106  
 animal cell 3, 4, 9, 10, 14, 36, 43, 45, 60, 87, 413  
 animal mitochondria 81  
 animal models 152, 296, 300, 302, 306, 370, 448  
 animal phylogeny 101  
 anion exchanger 111, 112  
   material 111  
 anionic liposome 169  
 annealing 148, 153, 253, 331  
 anode 107, 197  
 Anthrax 55  
 anti-apoptotic (Bcl2, BclX<sub>L</sub>) proteins 61  
 antibiotic(s) 18, 34, 52, 55, 84, 85, 159, 296, 317, 318, 327, 334, 368, 384, 385, 393, 403, 413, 445  
 antibiotic resistance 15, 162, 174, 176, 332, 334, 384  
   genes 54, 166, 382, 385, 404  
 antibodies 22, 33–34, 50, 56, 92, 119, 123, 125, 148, 167, 172, 193, 199, 205, 206, 223, 265–266, 268, 272, 300, 302, 312–315, 326, 334, 339–357, 376, 395, 413, 415–416, 422, 450  
   with human gene origins in mouse B cells 342  
 antibody coupling 313  
 antibody gene libraries 340–342, 356  
 antibody library 347  
 antibody-dependent cell-mediated cytotoxicity (ADCC) 350, 352  
 antibody-dependent cellular phagocytosis (ADCP) 350–352  
 antibody-dependent cytotoxicity 313  
 antibody gene libraries 340–342, 356  
 anticodon 81, 83  
 antigen(s) 22, 56, 315, 325, 334, 350, 355  
 antigen-binding antibody 339  
 antimicrobial peptides (AMP) 26, 34, 84  
 antiparallel chains 20  
 antiport 36  
 antisense RNA 29, 301, 370  
 AO (Acridine orange) 192  
 apoptosis 60, 61, 230, 239, 254, 256, 257, 350  
 apoptosis-inducing strategy 350  
 apoptosome 60, 61  
 apoptotic bodies 60  
 apoptotic protease activating factor (Apaf1) 61  
 applied microbiology 413  
 appropriate vector 159, 164, 174  
 AQUA peptides 121  
 aqueous solution 3, 106–108, 130, 199, 400  
*Arabidopsis thaliana* 95, 283, 380  
 arachidonic acid 14, 15  
 archaea 3, 63, 95, 96  
 array comparative genome hybridization (CGH) methods 334  
 ArrayExpress 279  
 array format 333, 334  
 Array-Tube<sup>®</sup> 335  
 arteriosclerosis 93  
 artificial neural networks (ANNs) 277, 286, 289–290  
 artificial promoters 377  
 aseptic tissue cultures 387  
 Asilomar moratorium 448  
 A-site 83  
 aspartate kinase 407–409  
 aspartate semialdehyde dehydrogenase 407  
 assay 121–122, 151, 177, 211, 223, 239, 242, 265, 291, 296, 298–300, 302–306, 323, 330, 337, 389, 431  
 assay for transposase-accessible chromatin using sequencing (ATAC-seq) 223, 291, 294  
 assembly algorithms 292  
 associated with some uncertainty 299  
 asymmetric structure 33, 35  
 atherosclerosis 300  
 atomic (AFM)/scanning force microscope (SFM) 199–201  
   advantages and disadvantages 201  
   force spectroscopy 200–201  
 AUG 81, 83  
 autism spectrum disorder (ASD) 371–372  
*Autographa californica* nuclear polyhedrosis virus (AcNPV) 177  
 automated protein expression 179  
 automated pump systems 109  
 automated test systems 403  
 autonomously replicating sequences (ARSs) 165  
 autoradiography 135  
 autosomes 67–68  
 auxiliary vector 163  
 auxin (indole-3-acetic acid) 385  
 auxins 379, 385, 387–388  
 auxotrophic mutants 403  
 auxotrophy genes 164  
 auxotrophy markers 164, 165, 176, 403  
 Aventis 449  
 8-Azaguanine resistance 410  
  
**b**  
 bacampicillin 317  
*Bacillus anthracis* 55  
 bacteria 3, 54, 95, 106  
 bacterial artificial chromosomes (BACs) 160, 364  
 bacterial azoreductases 319  
 bacterial cell(s) 3, 4, 9, 52, 54, 263  
 bacterial cell wall 18, 54, 106, 169  
 bacterial display 348  
 bacterial infections 55, 421  
 bacterial or yeast artificial chromosomes (BACS) 160, 364  
 bacterial replication origin 162  
 bacterial signal sequence 340  
 bacteriophage(s) 5, 6, 130, 138, 142, 161–164, 387, 402

- bacteriophage  $\lambda$  160, 162  
 bacteriophage T4 6, 142  
 baculoviruses 177–178  
 Bad protein 61  
 bait protein complex (RNAPol II)  
   123–124  
 Bak protein 61  
 base modification 29, 82  
 Basic Local Alignment Search Tool  
   (BLAST) 282, 294  
 Baum–Welch algorithm 286  
 Bax protein 61  
 B-cell receptors (BCR) 225, 227,  
   355  
 Bcl2 family 61  
 bedtools packages 294  
 beer production 393, 413, 445  
 Behringwerke 445  
 benzodiazepines 302  
 $\beta$ -pleated sheet structures 20  
 $\beta$ -sheet structure 20, 21  
 Betweenness centrality 243  
 Bid protein 61  
 Bim protein 61  
 binary vector 380–381, 386  
 binding assay(s) 303, 305  
 binding sites 21–23, 36, 38, 75, 83,  
   141, 147–149, 163–164, 174,  
   206, 242–243, 250, 256, 266,  
   270, 272, 278, 291, 294, 315,  
   333, 340, 342, 346–347,  
   353–354  
 Biocarta 279  
 biocatalysts, in chemical industry  
   bioconversion/enzymatic  
     procedures 395–397  
   enzyme(s) 395  
     development of a process 397  
     identification of products 397  
     lipases 400–401  
     nitrilases 400  
     novel biocatalysts 397–398  
     production of 399  
     rational and evolutive methods  
       401–402  
     requirements of 399  
   fermentative procedures and  
     bioconversion 394, 395  
   fermentative processes  
     *n*-Butanol 405–406  
     classical strain optimization  
       403–404  
     genomic research and  
       functional genomics 409  
     glutamic acid with  
       *C. glutamicum* 406–407  
     lysine with *C. glutamicum*  
       407–409  
     metabolic engineering  
       404–405  
     penicillin production 409  
     riboflavin 409–410  
     recombinant proteins 395  
   biochemical and cell biological  
     characters 5  
   biochemical assays 300, 303  
   Bioconductor project 294  
   bioconversion 394–397, 403  
   Biogen 448  
   Biogen Genentech 450  
   bioinformatic(s) 171, 414  
     evolution of 283–285  
     Gene Ontology 279  
     gene prediction  
       ANNs 286  
       comparative genomics 287  
       ESTs 287  
       HMMs 286  
     genome databases 278  
     molecular structure databases  
       278–279  
     motif databases 278  
     pathway databases 279–280  
     primary databases 277–278  
     reference databases 279  
     sequence analysis  
       alignment statistics 282  
       Helical wheel analysis 280  
       Kyte–Doolittle plot 280–281  
       multiple alignment 282–283  
       pairwise alignment 281–282  
       sequences of building blocks  
       280  
       signal sequence analysis  
       280–281  
     software 294  
   in transcriptome and proteome  
     analysis  
       correlation distance 289  
       DNA microarrays 287  
       Euclidean distance 288  
       feature selection 288  
       Gene Ontology 291  
       Mahalanobis distance 289  
       MALDI mass spectrometry  
       287  
       Manhattan distance 288–289  
       mutual information 289  
     supervised learning procedures  
       289–290  
     unsupervised learning  
       procedures 289  
   transcriptome databases 279  
   ultraparallel sequencing data  
     bioethics of 294  
     ChIP-seq 293  
     epigenetic analysis 293–294  
     genome (re-)sequencing 292  
     mapping of 291–292  
     single-cell analysis 294  
     transcriptome sequencing  
       292–293  
   bioinformatic annotation methods  
     409  
   biolistic transformation 381–382  
   biological(s) 299–300, 302, 308,  
     450  
   biological differences 288  
   biological safety research 376  
   biologics license application (BLA)  
     440  
   BioMed Central (BMC) 279  
   biomembranes 5, 9, 13–14, 33–37,  
     41–42, 47, 56, 87, 296  
   Biomodels database 252  
   biomolecular mass spectrometers  
     118  
   biosimilars 440–441  
   biosynthesis of glutamate 406  
   biotech company(ies) 302, 305,  
     414, 418, 420–421, 424,  
     448–451  
   appropriate environment 453  
   business plan 453  
   elements 453  
   employees  
     business attitude and  
       experience 457  
     business experience 456  
     high salaries 458  
     managers 456  
     motivation 458  
     qualified personnel 457  
     recruiting agencies 457  
     scientific and technological  
       competence 456  
     stock options 458  
     topic of remuneration 457  
   entrepreneurs 456  
   exit driven 454  
   financial plan 454  
   initial public offering (IPO) 455

- biotech company(ies) (*contd.*)
    - investors and venture capital
      - investors 454
    - management team 454
    - marketing 459
    - milestones 453
    - patent applications 453
    - PR and IR 461
    - realization plan 454
    - trade sale 455
    - venture capital and biotech
      - funding 456
  - biotech drugs 450
  - biotech financing 455
  - biotechnologically produced
    - products 393
  - biotechnology 393
    - access to data and materials 430
    - definition 413
    - MTAs 431
    - in volume and price different
      - 393
  - biotechnology industry
    - alcoholic fermentation 445
    - availability of venture capital 450
    - classical forms of 445
    - entrepreneurial environment
      - 451
    - factors 451
    - Genentech 447–449
    - genomics 450
    - marketing machineries 451
  - biotechnology patents
    - benefit sharing 432–433
    - commentators and industry
      - leaders 431
    - data and materials 430
    - ethical and policy concerns
      - 430–432
    - human dignity 429–430
    - legal and administrative 431
    - on nature 428–429
    - problems related to licensing
      - 431
    - reach-through licenses 431
    - reforms 432
  - biotin 149, 265, 288, 349, 406–407
  - biotin tags 349
  - bisacrylamide 108
  - bispecific antibodies 315, 347, 351,
    - 354–355, 357
  - bistable systems 254, 257
  - black body 209
  - BLAST 282, 294
  - blasticidin resistance 178
    - gene 165
  - blastocysts 364–367
  - bleomycin 384
  - block technological development
    - 425
  - blocking calcineurin 268
  - BLOSUM score matrices 281
  - BLUEPRINT 293
  - blunt ends 141–144, 161
    - DNA 142, 144, 161
  - B-lymphocyte 339, 341–342, 348
  - bone 420–421, 440
  - book-building phase 455
  - Boolean networks 243
  - Bordetella pertussis* 55
  - Boyer 414, 446, 447, 449
  - branching analysis 294
  - brand name recognition 461
  - BRCA1/2 genes 227, 299
  - bread production 413
  - breast cancer 218, 225, 229, 268,
    - 299–300, 354, 421, 460
  - bridge amplification 155–156
  - bromodomains 267
  - bromodeoxyuridine (BrdU) 193
  - bromoxynil 385
  - Brownian motion 261
  - budding index 191
  - building blocks for DNA and RNA
    - 25
  - building blocks for nucleic acids 25
  - Burrows–Wheeler transformation
    - 291
  - business development 453,
    - 459–460
    - manager 460, 461
  - business experience 456
  - butanol 393, 405, 413
  - bystander effect 354
  - bystander or passenger effect 291
- C**
- Ca<sup>2+</sup>-ATPase 35
  - Caenorhabditis elegans* 95, 123,
    - 217, 286, 298
  - caged molecules 211
  - calcium ions 169, 211
  - calcium phosphate-mediated
    - transfection 169
  - calf intestinal alkaline phosphatase
    - (CIP) 145
  - calling peaks 293
  - callus tissue 380, 387, 388
  - calmodulin-(CaM) dependent
    - kinases 38
  - Calvin cycle 47
  - Cambrian explosion 63
  - cameloid 205
  - cAMP 23, 24, 37, 38, 41, 55
  - cancer 299
    - driver mutations 226–228
    - patient 229, 231, 430
    - treatment 51, 229, 292, 350, 354
  - capillary electrophoresis (CE) 135,
    - 149, 153, 154, 335
  - carbenicillin 162
  - carbon-carbon bonds, formation of
    - 399, 401
  - carboxyl-/C-terminal 17
  - cargo protein 87–89, 92
  - carriers 25, 29, 35, 93, 311–313,
    - 315, 316, 318, 324
  - cartilage 420
  - Cas9 274, 275, 357, 361, 366, 367,
    - 376, 378
  - casein hydrolysate 176
  - Caspase-3 254–258
  - caspases 60, 61, 254
  - catabolism 49
  - catalytically active RNA 29
  - catalytic center 24, 157, 400
  - catalytic RNA molecules or
    - ribozymes 301
  - cathode 107, 197
  - cation exchanger 111, 112
  - cationic liposome 169
  - cauliflower mosaic virus (CaMV)
    - 390
  - C57BL/6 365, 366
  - ccdB* gene 163
  - CD and DVD players 211
  - CDK-inhibiting proteins 188
  - cDNA (copy DNA) 159, 177, 221
    - library 160
    - preparation 287
  - cell(s) 3
    - cultures 106, 122, 152, 178, 179,
      - 189–190, 195, 397, 413, 415
    - cycle 69, 72, 165, 167, 187–195,
      - 205–206, 222, 225, 229, 248,
        - 267, 288
    - cycle status 189
    - death 60–61, 68, 188, 254, 255
    - differentiation 56, 81, 187
    - disintegration 106, 108, 129, 130

- division 38, 51, 56, 68, 69, 71, 187–190, 192, 193, 325, 385, 388  
 lines 50, 165, 166, 177, 178, 206, 242, 243, 362, 427–430  
 nucleus 3, 48, 68, 87, 165  
 surface receptors 37, 55, 248  
 surface recognition strategy 313  
 walls 12, 18, 19, 52–54, 169, 381, 388  
 cell-attached configuration 182–184  
 cell cycle analysis  
   budding index 191  
   detection using fluorescent proteins 194–195  
   fluorescent staining of the nucleus 191–194  
   G<sub>0</sub> phase 188–189  
   interphase 187–188  
   mitosis, M-phase 188  
   synchronized cell cultures of *S. cerevisiae* 189–191  
 cell-fate decisions 248, 254  
 cell-free system 179–180  
 cell-penetrating antibodies 356–357  
 cell-suicide program 254  
 cell-to-cell interaction 37  
 cellular assays 302, 303  
 cellular carrier systems 316  
 cellular compartments 87, 95  
 cellular metabolism 49, 245, 384  
 cellular network  
   bottom-up modeling of  
     bistability 254  
     bistable systems 254, 257  
     calibration 252–254  
     caspase-3 (C3) 255  
     caspases 254  
     Michaelis–Menten equation 249  
     model complexity 248–251  
     model simulation 251–252  
     motivation 247–248  
     mutual inhibition mechanism 258  
     responsive transactivator (rtTA) 256–257  
     verification and analysis 254  
   metabolic network 239  
   signaling network 239  
   top-down approaches  
     Betweenness centrality 243  
     clustering coefficient 244  
     definition 240–241  
     elementary flux modes 244–247  
     gene regulatory models 242–243  
     gene set enrichment tests 241  
     machine learning system 244  
     motivation 240  
     reconstructing signaling networks 240  
     scale free networks 243  
     transcriptional regulatory network 239  
 cellular respiration 43  
 cellulase 12, 53, 382, 424  
 cellulose 10, 12, 53, 133, 135, 138, 311  
 Center for Biologics Evaluation and Research (CBER) 439, 440  
 Center for Devices and Radiological Health (CDRH) 440  
 Center for Drug Evaluation and Research (CDER) 439, 440  
 Center for Veterinary Medicine (CVM) 440  
 central nervous system (CNS)  
   diseases 462  
   in transgenic mice 364  
 centrifugal elutriation 190  
 centrifugation 66, 114, 115, 130, 131, 175, 190, 266, 349  
 centromere 51, 66–70  
 ceramides 14  
 cerebroside 14  
 cervical carcinoma 327  
 cetyltrimethylammonium bromide (CTAB) 130  
 CFTR gene 299, 324  
 cGMP 38  
 chain shuffling 348  
 channelrhodopsins 185  
 chaperones 83, 91  
 Chapman–Kolmogorov equation 285  
 characterization of proteins 105  
 charge/size ratio 108  
 cheese production 393, 413  
 chelating agents 113, 114  
 chemical modification 222, 223, 267, 317, 318  
 chemical modulators 298  
 chemical stable isotope labeling 121–122  
 chemical transformation 169, 396  
 chemically complex molecules 402  
 chemically difficult industrial reactions 399  
 chemically inducible promoters 377  
 chemokine receptor 326  
 chiasmata 70  
 chimeric antigen receptors (CAR) 347, 355, 357, 419  
 Chimeric Founders 365, 366  
 chimeric peptide 313  
 chimeric/humanized antibodies 339  
 ChIP on microarrays 241  
 ChIP-Seq 223, 270, 272, 291, 293  
 Chiron Genentech 450  
 chloramphenicol 317  
 chlorophyll 47, 388  
 chloroplasts 43–49, 81, 82, 88–89, 95, 378, 382, 388  
 cholera toxin 55  
 cholera-causing *Vibrio cholerae* 55  
 cholesterol 9, 13, 14, 16, 17, 93, 300  
   ester 93  
   levels 300  
 cholesterol-3-stearate 17  
 chromatids 51, 69–72  
 chromatin immuno precipitation (ChIP) 241, 242  
   by sequencing (ChIP-seq) 223, 241, 291, 293  
 chromatin remodeling complexes 69  
 chromatographic separation of nucleic acids 133–134  
 chromatographies and polishing 349  
 chromatography 106, 109–114, 117, 124, 130, 133–135, 164, 172, 265, 346, 349  
 ChromHMM 293  
 chromosomal DNA 129  
 chromosomal orientation 80  
 chromosome(s) 42, 46, 51, 54, 60, 61, 63–75, 80, 130, 139–140, 160, 162, 176, 187–188, 218–219, 223–227, 232, 299, 324, 327–329, 337, 364, 366, 378–379, 381–382, 387, 389–390  
 chromosome mutations 72

- chromosome mutations (*contd.*)
- chronic myeloid leukemia (CML) 225, 227, 299, 329
- Cibacron Blue 112, 114, 115
- Cibacron Blue-Sepharose CL-6B column 114
- Cibacron F3G-A 112
- cilia 51, 53
- CIP/KIP family (CDK-inhibiting proteins kinase-inhibiting proteins) 188
- 2  $\mu$ m circle plasmid 165
- circular bacterial genomes 72
- circular species of DNA 130
- citric acid cycle 25, 44, 45, 50, 52
- clamp loader 71
- classic virus diagnostics 326
- classical forms of biotechnology 445
- classical organic chemistry 446
- classical strain development 403, 404, 409, 410
- classical strain optimization 403–404
- clathrin molecules 92
- cleavable linkers 354
- clinical study phase I 307
- clinical study phase II 307
- clinical study phase III 307
- clinical study phase IV 307, 308
- clonal selection 340, 342
- clones 159, 160, 165, 166, 168, 176, 177, 294, 346, 348, 352, 365
- cloning 427
  - antibiotic resistance 162
  - bacterial replication origin 162
  - eukaryotic expression vectors 164–168
  - fusion sequence 164
  - heterologous DNA 168–169
  - insert 159–161
  - polylinkers 162
  - promoter 163
  - recombination system 162–163
  - ribosome-binding site (RBS) 163–164
  - termination sequence 164
  - vector 161–162
- cloning strategy 161, 164
- cloud system 292
- ClustalW 282, 283
- clustered regularly interspaced short palindromic repeats (CRISPRs) 226, 274
- clustered regularly interspaced short palindromic repeats/ endonuclease Cas9 (CRISPR/ Cas9) 29, 274, 297–298, 357, 361, 366, 367, 376, 378
- clustering coefficient 244
- clustering procedures 289
- Co affinity 349
- CO<sub>2</sub> fixation process 47
- co-immunoprecipitation (Co-IP) 123
- coding 22, 35, 45, 57, 77, 131, 163, 240, 244, 278, 285–287, 295–296, 298, 316, 326–328, 366, 371, 378, 383
- coding strand 75, 80
- codons 75, 81, 164, 174, 286, 328, 366
- coenzymes 23, 25
- cognitive disorders 370, 371
- Cohen 159, 414, 446
- coherent anti-Raman scattering (CARS) 212, 355
- coiled coil 21
- color spectrum 209
- column chromatography methods
  - chelating agents 113–114
  - Cibacron Blue 112
  - glutathione matrices 114
  - heparin 113
  - hydrophobic interactions 111
  - hydroxyapatite 112
  - ion exchange chromatography 111–112
  - lectins 112–113
  - protein A 112
  - protein G 112
  - size exclusion chromatography 109
- combinatorial chemistry 302, 303, 316
- commercially available enzymes 397
- commercially available vectors 176
- Committee for Advanced Therapies (CAT) 436
- Committee for Medicinal Products for Human Use (CHMP) 436, 437
- Committee for Medicinal Products for Veterinary Use (CVMP) 436, 437
- Committee for Orphan Medicinal Products (COMP) 436
- Committee on Herbal Medicinal Products (HMPC) 436
- common ancestors 283, 285
- comparative genomics 287
- Comparative Regulatory Genomics (CORG) database 287
- compartments 5, 13, 41, 42, 50, 60, 87, 91, 92, 95, 150, 156, 185
- compatible sticky ends 161
- competent bacteria 169
- competitor 350, 422, 425, 426, 431, 432, 454, 456, 459
- complement component 1q (C1q) 349, 352
- complement-dependent cytotoxicity (CDC) 350, 352
- complementarity-determining regions (CDR) 339, 340
- complementary base pairing 27, 28
- complementary double strands 82
- complementary nucleic acid strands 137
- complete IgG molecule 347, 348, 352, 355
- complex molecular apparatus 340
- composition of matter patent 301
- compound annual growth rate (CAGR) 415
- compound libraries and screening procedures 302
- compound transgenic mice 361, 368
- compulsory licensing 425
- computational biology 377, 422
- condensation reactions 9
- conditionally-regulated gene expression 367–368
- confocal laser scanning microscopes 203
- confocal microscopy 202–203
- conformation change 37, 92
- conformational change 24, 49, 88, 181, 274
- conformations 19, 223, 350
- consecutive kinase-phosphatase interactions 248
- consensus sequences 76, 77
- constant domains 339, 350, 352, 354
- constitutive expression of recombinant protein 163, 165, 166

- constitutively active promoter 176, 178  
 constitutively active/inducible promoters 164, 176, 178  
 continuous wave lasers (“cw”) 210  
 contributory infringement 427  
 controlled access model 294  
 controversial distinctions 429  
 convergent evolution 95  
 Coomassie Blue R-250 108, 115  
 Coomassie-based staining reagents 108  
 cooperativity 28, 242, 248, 250, 252, 264  
   of many hydrogen bonds 28  
 COPI proteins 92  
 COPII proteins 92  
 copy-number variants 229, 292  
 copyrights 425  
 co-receptor, HIV 326  
 corporate guidelines 451  
 corporate image 456, 461, 462  
 correlation 206–207, 288–289, 299, 370, 377, 409  
 correlation distance 289  
 correspondence analysis (CA) 289  
 cortisol 16, 17  
 cosmids 160  
 cost estimate for sequencing 218  
 cost-effective high-throughput sequencing technologies 337  
 cotransformation 162, 163, 386  
 counter-selectable markers 383  
 counting cells under the microscope 192  
 coupling function 346  
 coupling or linkage analysis 325  
 covalent bonds 19–23, 27  
 covalent modifications 121, 267  
 covalently linking 112  
 cowpea mosaic virus (CPMV) 383  
 Cre/lox 368, 370, 387  
 CRISPRs (clustered regular interspaced short palindromic repeats) 226, 274  
 CRISPR/Cas9 (clustered regularly interspaced shortpalindromic repeats/endonuclease Cas9) 29, 274, 297, 298, 357, 361, 366, 367, 376, 378  
 CRISPR-mediated immunity 29  
 critical process step, plant biotechnology 387  
 crop plants 375–378, 385, 386, 389  
 cross-breeding 159  
 cross-licensing 461  
 crossing over 66, 67, 70  
 cross-talk for protein interaction 49  
 crown galls 379  
 cryo-electron microscopy (cryo-EM) 199  
 C-terminus peptid sequence 119  
 curated database 278  
 cut ligation 161  
 Cy5 135  
 cyan fluorescent protein (CFP) 266  
 cyanobacteria 3, 47, 49, 95, 378  
 cyclical nature of biotech valuations 456  
 cyclin(s) 187–188, 190, 267  
 cyclin dependent kinases (CDKs) 187, 188, 267  
 cyclooxygenase 15  
 cystic fibrosis 299, 324  
 cystic fibrosis transmembrane conductance regulator (CFTR) gene 299, 324  
 cytidine 72, 75, 231  
 cytochrome oxidases 42  
 cytochrome P450 oxidases 326  
 cytogenetics 139  
 cytokinesis 70, 188, 195  
 cytokinins 379, 385, 387, 388  
 cytomegalovirus 165  
 cytoplasm 42, 48–50, 54, 80, 83, 87, 89, 131, 202, 221, 267, 340, 353, 356–357  
 cytoplasmic membrane 33, 36, 42, 46, 47, 50, 51, 54, 87, 92, 93, 181, 183  
   membrane permeability 33–34  
   receptors and signal transduction at biomembranes 36–41  
   transport processes across biomembranes 34–36  
 cytosine 25, 72, 73, 80, 83, 137, 142, 191, 223, 293, 327, 330, 332, 403  
 cytoskeletal structures 54  
 cytoskeleton 3, 38, 50–52, 60  
 cytosol 38, 49, 50, 61, 78, 83, 87–89, 91, 114, 115  
 cytostatic drugs 311, 312, 315, 318  
 cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 353
- d**
- Danio rerio* 95, 298  
 DAPI 139, 191, 192  
 dark-field microscopy 199, 201  
 data access agreements 294  
 daunomycin 315, 320  
 dbGap 279  
   database 294  
 3D crystal structure 304  
 de-Bruijn-graphs 292  
 de-novo sequencing 121, 281, 292  
 DEAD-box RNA helicase family 297  
 deamination 72–75, 327, 410  
 death-inducing signaling complex (DISC) 61  
 decision trees 289–290  
 deCODE 226  
 deconvolution 202  
 DeepBlue 293  
 defective LDL receptor genes 93  
 defense/signaling compartment 43  
 defined electrical charge 107  
 degenerate codons 81  
 degradation of glucose to pyruvate 50  
 degradation of organic matter 49–50  
 degree of cross-linking 107–108  
 denaturation 105, 108, 135, 148, 153, 341  
 denatured protein 20  
 denaturing conditions 114, 175  
 deoxyribonucleic acid (DNA) 25–32, 63–85, 129–131, 133–135, 137–145, 147–169, 217–232, 261–275, 325–338, 362–369, 376–383, 386–390, 397–398, 403–404, 409, 426–432, 446–450  
 dephosphorylation 20, 24–25, 40, 49, 52, 251  
 depurination 72–75  
 DESeq2/edgeR 293  
 Designer Receptors Exclusively Activated by Designer Drugs (DREADD) 372  
 desoxyribonuclease I (DNase I) 144, 291

- destaining solution 108  
 detection of antibodies 326, 334  
 deuterostomia and vertebrates 100  
 development of selective and sustainable production processes 399  
 Devonian period 63  
 dexamethasone-21- $\beta$ -D-glucoside 319  
 Dextran Blue 2000 110  
 diacylglycerol (DAG) 38, 41  
 diakinesis 70  
 diaminopimelate decarboxylase (LysA) 408–409  
 diaminopimelate dehydrogenase (Ddh) 408  
 Dicer 29, 370  
 dideoxyribonucleoside triphosphates (ddNTPs) 153–154, 336  
 diethylaminoethyl (DEAE)-Sephacrose 111  
 differential expression profiles 297  
 differential/alternative splicing 80  
 digital PCR (dPCR) 150–151  
 digital quantitative PCR 331  
 dihydrodipicolinate synthase 407  
 dihydrotrigonellin  $\leftrightarrow$  trigonellin vector system 318  
 1,4-dihydrotrigonellin derivatives 318, 319  
 dimerization 38, 72–74, 352  
 dimethyl sulfoxide 169  
 dinucleotide repeats 328  
 Diphtheria Toxin Repressor (DtxR) 269  
 dipivefrin 318  
 diploid 69–71, 73, 75, 121, 165, 187, 189, 191, 218–219, 324  
 diplomonads/trichomonads 3  
 diplotene 70  
 direct infringement 427  
 direct to consumer testing (DTC) 231  
 directed evolution 399, 402, 414  
 disaccharide 9, 11–13, 409  
 disarmed Ti-plasmid 380  
 discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 107–108, 114  
 diseases 55, 225–226, 323–326, 370  
 disintegration 106, 108, 129–130  
 dissociation constants 264, 266  
 distribution of the cell population 192  
 distributive justice 433  
 disulfide bonds 107, 340, 352  
 disulfide bridges 19–20, 24, 175, 177, 348  
 disulfide-stabilized Fv (dsFv) antibody 351–352  
 dithiothreitol 107  
 divide and conquer (DCA) 283  
 division of labor 29, 56, 60  
 DNA arrays 60, 409  
 DNA chips 75, 277, 287, 334, 409, 421–422, 431  
 DNA Database of Japan (DDBJ) 277–278  
 DNA fingerprinting 27, 67, 138  
 DNA fragments size 134  
 DNA from viruses/bacteriophages 130  
 DNA intercalators 27  
 DNA isolation 129–131  
 DNA ligase 71–73, 113, 142  
 DNA manipulation 159  
 DNA methylation 81, 242, 283, 291, 293, 330  
 DNA microarray technology 279, 287–288  
 DNA microarrays 287, 290, 334  
 DNA-modifying activity 296  
 DNA polymerase(s) 67, 69, 71–73, 75, 87, 143–144, 147, 148, 151, 153–154, 157, 219, 328, 331–333, 336, 339  
 DNA polymorphisms 390  
 DNA primase 71, 73  
 DNA rearrangements 29, 72  
 DNA repair 77, 81, 274  
 DNA replication 71–72, 187–189, 217, 225, 327–328  
 DNA sequences 65–66, 72, 80, 141, 143, 144, 147, 149, 153–155, 157–158, 172, 174, 176, 217, 268–269, 273–274, 293, 299, 323, 325, 330–331, 334, 346, 364–365, 367, 378, 390, 418, 426, 428–429  
 specific protein recognition 141, 269  
 DNA sequencing  
   impact of 158  
   pyrosequencing 154–155  
 Sanger enzymatic sequencing method 153–154  
 second generation sequencing methods 155–156  
 third generation sequencing techniques 156–158  
 DNA topoisomerase I 72  
 DNA topoisomerase II 72  
 DNase I 143, 144, 291  
 DNase I hypersensitive sites sequencing (DNase-seq) 291, 294  
 docking of ligand–receptor association 304  
 dolichol diphosphate esters 91  
 domain combination 66  
 domain shuffling 22  
 dominant diseases 324  
 dominant marker 165  
 Donnan effect 112  
 donor fluorophore 303  
 donor vector 163  
 dose–response curve 305  
 double helix 27–28, 67, 71–73, 75, 143–144, 231, 270  
 double prodrugs 317  
 double strands of complementary nucleic acid sequences 137  
 double-stranded DNA 130, 133–134, 141–145, 147–150, 159, 275, 331–332, 367  
 down-regulation 377  
 downscaling 403  
 downstream inventions 431  
 doxycycline (Dox) 166, 256, 368  
 3D printing 213  
 DRAQ5 191–192  
 3D structure 199, 296, 420–421  
 driver mutations 226–228, 299  
*Drosophila melanogaster* 95, 140, 178, 298  
 drug approval  
   EU regulatory framework  
     EMA 436–437  
     medicinal products 435, 436  
     pharmaceutical law 435  
     principles of 435  
   ICH 441–442  
   in US regulation  
     biosimilar 440–441  
     CBER 439–440  
     CDER 439–440  
     FDA 438–439  
 drug design 21



- drug research  
 active compounds and targets  
 biologicals 299–300  
*in vitro* methods 297–298  
 comparative genome analysis 297  
 compound libraries and screening procedures 302–305  
 disease genes 298  
 DNA and RNA in 300  
 efficacy and potency 305  
 high-quality paramounts in screening assays 302–303  
 high-throughput screening 302  
 Human Genome Project 296–297  
 lead structure 305–306  
 model organisms 298  
 patent protection 301–302  
 target candidates and genuine targets 299  
 therapeutic agents 295  
 virtual ligand screening 304–305  
 clinical development 307  
 clinical testing 307–308  
 new conditions 295  
 preclinical pharmacology and toxicology 306–307
- drug targeting  
 active targeting 313–316  
 cellular carrier systems 316  
 passive targeting 311–312  
 physical drug targeting 312
- druggability 296, 299  
 due diligence 426  
 duplication of a gene 328, 329  
 dye laser 210  
 dyes 50, 108, 112, 114, 134–135, 139, 149–151, 153–154, 156–157, 185, 191–193, 203–205, 210–211, 288, 302, 316, 332–333, 335
- dynamic programming 282
- e**  
 economic strategy 462  
 economical advantages 396  
 ecotropic retroviruses 168  
 edema factor 55  
 effective chemotherapies 445
- effective concentration 50% (EC<sub>50</sub>) 305  
 effector functions 350, 352, 354  
 effector mechanisms 339  
 efficient and reproducible selection 384  
 egoistic genes 67  
 eicosanoids 14  
 electric field 107, 133–134, 157  
 electric impulse 169  
 electromagnetic waves 209  
 electron microscopy  
 cryo-electron microscopy (cryo-EM) 199  
 electron tomography 199  
 scanning transmission electron microscope (STEM) 198–199  
 transmission electron microscope (TEM) 197–198  
 electron tomography 199  
 electron transfer dissociation (ETD) 119, 121, 124  
 electronegative atoms 19  
 electrophoresis 133  
 agarose gel electrophoresis 134  
 polyacrylamide gel electrophoresis (PAGE) 135  
 pulsed field gel electrophoresis (PFG) 134–135  
 electroporation 169, 179, 341, 357, 365, 368–369  
 electrospray ionization (ESI) 117–119, 121  
 elementary flux modes 244–247  
 Eli Lilly and Co. Lilly 448  
 Eli Lilly company 414  
 elongation 50, 113, 123, 148, 150–151, 153, 156, 180, 238  
 elution 107, 109–114, 347  
 elution volume 110  
 elutriation rotor 190  
 EMBOSS project 294  
 embryonic bodies 364, 366  
 embryonic stem (ES) cells 56–57, 362, 364, 419, 430  
 embryos 56, 267, 274, 361–369, 380, 386–387, 430  
 emission 149, 151, 157, 191–192, 203, 207, 209–212, 303  
 EMMA 362  
 employee stock option (ESO) scheme 458  
 enabling technologies 376, 416
- enantiomerically pure  
 α-hydroxycarbonic acids 400  
 ENCODE project 223–224, 242, 293  
 endocrine signals (hormones) 37–38  
 endocytosis 33, 36, 42, 92–94, 169  
 endocytosis–exocytosis cycle 93  
 endogenous proteins 176, 205–206  
 endomembrane system 41–44, 54, 92  
 endonuclease(s) 61, 73, 138, 141–144, 159, 223, 274–275, 333, 361, 366–367, 378  
 endonuclease-based knock-in mice 367  
 endonuclease-based knock-out mice 366–367  
 endoplasmic reticulum (ER) 33, 35, 38, 41–42, 44, 46–47, 83, 87, 89–94, 106, 211, 356–357  
 endosomes 42, 87, 92  
 endosomes and lysosome 92, 93  
 endosymbiont hypothesis 45, 382  
 endosymbiotic origin 47, 95  
 endosymbiosis 48  
 energy carriers 25  
 energy production 44  
 energy-rich radiation 72  
 Engineering Biology Research Consortium (EBRC)  
 synthetic biology 422  
 enhance the bioavailability 306  
 enhanced permeability and retention (EPR) effect 311–312  
 enhancer 67, 77, 79, 223–224, 226, 293, 327–328, 369, 377, 379, 393, 406  
 enhancer RNAs 221  
 enrichment procedure 105, 109–110, 113–114, 124, 131, 137, 147, 171, 220–221, 240–241, 291–293, 346, 354, 397, 400  
 Ensembl 222, 254, 278, 290  
 ENSEMBL genome browser 224  
 ensemble modeling approach 254  
 entry vector 163  
 enzymatic activity 107, 108, 114, 167, 383, 389  
 enzymatic and mechanical lysis 106  
 enzymatically active proteins 105

- enzyme-linked receptors 38, 44  
 enzymes 22, 36, 38, 141–145, 204, 244, 295, 397–402, 408–409  
 enzymes as biological catalysts 23  
 epigenetic analysis 293–294  
 epigenetic inheritance 81, 283  
 epigenetics 81, 223, 230, 242, 283, 293–294, 329–330  
 epinephrine 318  
 equilibrium centrifugation 266  
 ER import signal peptide 89  
 ER lumen 89–91  
 ER targeted intrabodies 356  
 error rates 72, 144, 148, 153, 155, 157, 161, 218, 292, 325  
 erythropoietin 176, 179, 268, 450  
*Escherichia coli* (*E. coli*) 52, 55, 76, 82, 95, 105, 113–115, 141–144, 159, 162–168, 171–172, 174–180, 205, 217, 220, 245, 247, 258, 297, 341–342, 346–349, 351, 363, 365, 380–381, 383–384, 399, 403–405  
 E-site 83  
 essential amino acids 19, 122, 376, 407  
 essential needs of the species 387  
 ester prodrugs 317  
 esterases 93, 317, 396  
 $\beta$ -estradiol 16, 17  
 estrogens 17, 229, 274  
 ethics commission 307  
 ethidium bromide (EtBr) 130, 134, 191  
 Euglenozoa 3  
 eukarya 3, 5, 63, 90  
 eukaryotes 3, 9, 13, 17, 27, 29, 35, 41, 44, 54, 57–58, 63, 65–67, 69, 71–72, 75–76, 78–81, 95–101, 121, 124, 129–130, 161, 164–165, 177, 187, 217, 220, 223, 270, 380  
 eukaryotic cell 3, 4, 95–101  
   cell walls 52–54  
   cytoplasm 49–50  
   cytoplasmic membrane 33–40  
   cytoskeleton 50–52  
   endomembrane system 41–43  
   mitochondria and chloroplasts 43–49  
 eukaryotic chromosomes 72  
 eukaryotic elongation factor EF2 $\alpha$  165–166  
 eukaryotic expression systems 164  
 eukaryotic expression vectors  
   mammalian cells 165–167  
   viral expression systems for  
   mammalian cells 167–168  
   yeast 164–165  
 eukaryotic nucleus 42  
 eukaryotic protein secretion  
   mechanism 175  
 eukaryotic ribosome 29, 81–82, 84  
 Euler method 252  
 European Genome-Phenome  
   Archive (EGA) 227, 279, 294  
 European Medicines Agency (EMA)  
   activities 436  
   centralized procedure 437–438  
   clinical practice 436  
   committees 436, 437  
   decentralized procedure 438  
 EU medicinal product regulation 436  
 mutual recognition procedure 438  
 novel and advanced therapies 436  
 structure of 436, 437  
 European Medicines Evaluation  
   Agency (EMA) 436, 440  
 European Molecular Biology  
   Laboratory (EMBL)  
   277–278  
 European Nucleotide Archive (ENA) 279  
 European Patent Office (EPO) 430  
 even whole chromosomes 135, 219, 225  
 evolution of chordates 63  
 evolutionary bioinformatics  
   intelligent design 283  
   Neo-Darwinian Synthesis 283  
   phylogenetic analysis 285  
   score matrix 284–285  
   statistical model of 283–284  
 evolutionary coupling 266–267  
 executioner caspases 60–61  
 excision 107, 212, 376, 379, 386–387  
 excisionase 162, 163  
 exclusion chromatography 109–110, 133  
 exclusion volume 110  
 exocytosis 33, 87, 92, 93  
 exome sequencing 220–221, 226–227, 231, 292  
 exons 45, 67, 75, 79, 155, 177, 285–286, 292, 365, 368  
 exons in a eukaryotic gene 22  
 exonuclease(s) 68, 72, 143–144, 148, 150  
 exonuclease I 144  
 exonuclease III 144  
 3'  $\rightarrow$  5' exonuclease 143  
 5'  $\rightarrow$  3' exonuclease 143  
 export receptors (exportins) 80, 88  
 exportins 88  
 expressed sequence(s) 79  
 expressed sequence tag (EST) 63, 221, 226, 286–287  
 expression control 266, 377  
 expression systems are bacterial  
   systems 171  
 expression vectors 152, 162–168, 171–172, 174, 178, 205, 288, 340, 342  
 Extended-spectrum  $\beta$ -lactamase (ESBL) 55  
 extrinsic pathway 61
- f**  
 Fab antibodies 354  
 FADH<sub>2</sub> 43, 50  
 fair distribution 432, 433  
 Faroe Genome Project (FARGEN) 226  
*Fas* death receptor 61  
 Fas-ligands 61  
 fast protein liquid chromatography (FPLC) 106, 109, 114  
 FASTA 282  
 Fc engineering 352  
 Fc receptors (FcR) 349  
 Federal Food, Drug, and Cosmetic (FD&C) act 438  
 fee-for-service deals 460  
 feedback resistor 182, 183  
 fenestrated endothelium 311  
 fermentation processes 176, 393, 395, 396, 399, 402–406, 409, 413, 445  
 fermentative Penicillin production 409  
 fermentative procedures 393–395, 402–410  
 fermentative production of  
   glutamate 406

- fibroblast growth factors (FGF) 113, 267
- filamentous phage M13 346, 347
- financial plan 454
- financing deal 461
- first therapeutic antibodies 415
- FK506-binding protein (FKBP) 268
- flagella 51, 53, 54, 348
- flow cytometer 191, 192
- flow cytometry 151, 187, 192, 194–195, 212, 325
- fluid-phase endocytosis 93
- fluorescence 203
- fluorescence *in situ* hybridization (FISH) 68, 139
- fluorescence correlation spectroscopy (FCS) 206–207
- fluorescence decay 207
- fluorescence lifetime imaging microscopy (FLIM) 207
- fluorescence microscopy 167, 205, 207
- fluorescence recovery after photobleaching (FRAP) 206
- fluorescence resonance energy transfer (FRET) 207, 266, 303, 305, 332, 333
- fluorescent dyes 50, 135, 149–151, 153, 154, 156, 157, 185, 191, 203, 205, 211, 288, 316, 332, 333, 335
- fluorescent labels 138, 325, 333, 336
- fluorescently labeled proteins 205, 206
- 5-fluorouracil 320
- Flux Balance Analysis (FBA) 247
- folding of antibodies 340, 349, 356
- Food and Drug Administration (FDA) 308, 316, 337, 351, 415, 435, 438–440
- foodstuffs 393, 395, 413, 423
- force spectroscopy 200–201
- forced protein association 355
- N*-formylmethionine 81
- Förster resonance energy transfer (FRET) 207, 266, 303, 333
- fosphenytoin (Cerebyx®) 316, 317
- Fourier transform (FT) 204, 288
- Fourier transformations 288
- F plasmids 162, 217
- FPLC system 114
- fragment length analysis
- amplification-created restriction sites (ACRS) 336
- ARMS 336
- length polymorphism, PCR detection 335
- minisequencing 336
- mutationally separated (MS)-PCR 336
- RFLP 335
- unknown mutations, determination of 336
- fragments/reads per kilobase per million (FPKM/RPKM) 292
- frameshift(s) 28, 66, 75, 81, 227, 287, 326, 328, 329, 366, 367, 378, 403
- mutation 28, 75, 227, 328, 329, 366, 403
- framework regions 339
- free and facilitated diffusion 35
- free ribosomes in the cytoplasm 83, 89
- French press 106
- frequently used tags 167, 172
- fruit fly (*Drosophila melanogaster*) 95, 140, 178, 298
- fully human antibody therapeutics 350, 351
- functional (significant) mutations 327
- functional foods (nutraceuticals) 376, 423
- functional genomics 60, 63, 294, 356, 409
- functional ribosomes 45
- functionally validating targets 462
- fungal cells 52
- fusion protein 113, 114, 164, 166, 167, 172, 175–178, 195, 205, 206, 227, 265, 316, 327, 329, 332, 346, 352–354, 357
- CH1/CL fusion proteins 352
- expression 164
- fusion sequence 164, 167
- future protein therapeutics 357
- g**
- GABA receptor 37
- G actin 50, 52
- galactose-inducible promoters 164
- galacturonic acid 12
- Galaxy servers 292
- galenics 306
- gametes 67, 69, 73, 75, 81, 218, 430
- gangliosides 14, 16
- gated transport 87
- Gateway® system 162
- gel electrophoresis 107–108, 115, 134–135, 149, 287, 330, 335–336, 389, 409
- gel electrophoretic separation methods 153
- isoelectric focusing (IEF) 108
- native gel electrophoresis 107
- principles of electrophoresis 107
- protein detection in gels 108
- sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 107–108
- two-dimensional (2D) gel electrophoresis 108
- gel filtration 109–110, 129, 133, 349
- GenBank 221, 277–279, 290
- gene arrays 139
- gene chips 139, 421
- gene cloning 159
- gene diagnostics 130
- gene duplication 22, 66, 329–330, 332
- gene-edited mice 361, 366–367
- gene editing 29, 274, 362, 364, 366–367, 370
- gene expression control 376–378
- Gene Expression Omnibus 227, 279
- gene expression studies 152
- gene family 296–297
- gene farming 423
- gene guns 381, 387
- gene mutations 72, 77, 361, 363, 370
- gene of interest (GOI) 168, 242, 363, 368, 377, 380, 382, 390
- Gene Ontology (GO) project 241, 279–280, 291
- gene overexpression 403
- (gene) panel sequencing 220–221
- gene regulation 29, 65, 80–81, 240, 243, 269, 278, 368
- gene regulatory models 240, 242–243
- gene set enrichment analysis 291
- gene-silencing effects 382
- gene switches 377

- gene-targeted mice 361, 363–366, 368, 370
- gene targeting 362, 364–365, 367
- gene therapeutic methods 301
- gene therapy 56, 60, 302, 357, 369, 416–419, 425, 427
- gene to protein transcription 75–81
- gene transfer to cell sub-populations  
  electroporation of mouse embryos 368–369  
  virus-mediated gene deletion (Cre/lox) 370  
  virus-mediated gene knock-down 370  
  virus-mediated gene transfer 369–370
- GeneCards 279
- Genentech Inc. 300, 414, 424, 447–449
- General Data Protection Regulation (GDPR) 294
- generally recognized as safe (GRAS) 176, 177
- generated *in vitro* 339
- genes or cell lines 428
- genetic code 19, 45, 74, 81, 159, 329, 446
- genetic combinatorics 339
- genetic comparisons 299
- genetic differences 299, 326
- genetic diversity 340–341
- genetic engineering 12, 24, 28, 56, 142, 144, 149, 300, 339, 375–376, 385–387, 393, 409, 423, 441, 445–449
- Genetic Engineering Law 376
- genetic fingerprints 325, 328
- genetic information 25, 29, 42, 54–56, 70, 73, 75, 78, 168, 218, 220–221, 224, 226, 229, 232, 294, 323, 346, 351, 355, 365, 446
- genetic inventory of pathogenic microorganisms 297
- genetic mutations 327, 370
- genetic polymorphisms 139, 294, 324, 326
- genetic recombination 325
- genetic risks 139, 324
- genetically modified mice  
  ALS 370–371  
  cognitive disorders 371  
  psychological disorders 371
- genetically modified organism (GMO) 147, 375–376, 378, 410
- genetically modified production 352
- Genetics Computer Group (GCG) 294
- geneticin (G418) 384
- genome 63  
  databases 278, 398  
  duplications 63, 65  
  editing 361–363, 367, 372–373, 376–378  
  1000 genomes project 224–226  
  (re-)sequencing 281, 291, 292, 337  
  size 63–67
- genome-wide association studies (GWAS) 225, 299, 375
- genomic(s) 60, 63, 222, 229, 287, 294, 302, 356, 375, 409, 414, 416, 421–423, 450, 455
- genomic DNA 130, 138, 155, 159–160, 178, 275, 326, 327, 330, 364, 378
- genomic imprinting 81
- genomic PCR 363, 388
- genotyping 151, 325–326, 330, 376, 378
- GENSAT program 364
- gentamicin 384
- Genzyme Genentech 450
- germ line mutations 158, 227, 229, 325
- gigaohm contact 182
- Gilbert, Walter 153, 448
- glaucoma 318
- global alignments 281–282
- globaltest 291
- glucocorticoids 17, 274
- glucosamine 9
- glucose transporters 36, 37
- $\beta$ -glucosidase 43
- glucuronic acid 9, 12, 319
- $\beta$ -glucuronidase 298, 381
- glucuronidases 385
- glufosinate 384
- glufosinate resistance 385
- glutathione matrices 114
- glutathione S-transferase (GST) 113–114, 172, 175–177, 265, 349
- glycerol 14, 34, 47, 111, 115, 169
- glycine receptor 37
- glycoengineering methods 352
- glycogen 10–11
- glycolipids 13, 16
- glycolysis 10, 44, 50, 52, 245, 405
- glycoprotein G from vesicular stomatitis virus (VSV-G) 168
- glycoproteins 19, 91, 112–113, 264, 317
- glycosaminoglycan 113
- glycosidases 42, 320
- O-glycosidic 19, 91
- glycosidic bond 9–10, 12
- N-glycosidic bond 19, 25, 91
- glycosylation 19, 119, 171, 176, 178, 352, 382, 441  
  of antibodies 349  
  sites 352
- glycosyl phosphatidylinositol (GPI) anchor 92
- glyphosate 384
- glyphosate tolerance 384
- goals of strain development 403
- GoldenPath Browser 278
- Golgi apparatus 87, 91, 92, 106
- Golgi complex 41–42, 44
- Gonnet series 281
- Good Clinical Practice (GCP) guidelines 307, 436
- G<sub>0</sub> phase 188
- G<sub>1</sub> phase 72, 187
- G<sub>2</sub> phase 72, 188
- G-protein 37–38, 43–44, 55, 114–115
- G protein-coupled receptors (GPCRs) 37, 40, 44, 181, 270, 296, 302, 372
- gram-negative bacteria 52, 54, 95, 340, 349
- gram-positive bacteria 52, 54, 406
- gray biotechnology 414
- green algae/plants 3, 97
- green biotechnology  
  agriculture and food production 422  
  functional food 423  
  genomic approaches in 423  
  livestock breeding 423  
  transgenic plants 422–423
- green fluorescent protein (GFP) 50, 167, 184, 192, 195, 199, 204–206, 257, 265, 364, 368–369, 381
- green genetic engineering 375–376

- green plants 46  
growth factors 37–38, 113, 252, 267, 348, 388, 415, 420, 422  
growth hormone 300, 423, 441, 450  
growth hormone genes 361, 362  
GST fusion proteins 113, 114  
GST tags 113–114, 175–176, 349  
GTP-binding protein (Ran-GTP) 88  
GTPase activating protein (GAP) 25, 88, 114  
guanidinium isothiocyanate (GTC) 131  
guanine exchange factor (GEF) 25, 44, 88  
guanosine 72, 231  
guanosine diphosphate (GDP) 24–25, 37, 40, 49, 51, 88, 268  
guanosine triphosphate (GTP) 24, 37, 410  
gyrase 163
- h**  
half-life 230, 312, 315, 350, 352, 354  
Halorhodopsin 372  
HAMA responses 350  
haploid genomes 64, 218  
haploids 63–65, 69, 70, 158, 165, 187, 189–191, 218, 219, 388  
Hatch Waxman act 441  
headhunters 457  
heat shock 83, 169  
heat-shock proteins 83  
Helical wheel analysis 280  
helicase 71, 296  
 $\alpha$ -helix 20–21  
 $\alpha$ -helix structures 20  
helper phage 346  
helper plasmids 369, 380  
hemoglobin mRNA 180  
heparin 12, 113  
hepatitis C virus (HCV) infections 326  
HER2 protein 313  
herbicide resistance 376, 383, 384  
Herceptin 268, 300, 313, 421  
heterokonts 3  
heterologous DNA 159, 160, 165, 168, 169  
heterologous expression 163, 166, 167, 171, 183–185, 339, 350  
heterologous gene(s) 167  
heterologous gene expression 163, 166, 167, 171, 183–185, 339, 350  
heterozygote 75, 78, 324, 329, 330, 335, 365, 388  
heterozygote character 75  
heterozygous 292, 324, 335, 363–365  
heterozygous carriers 324  
heuristic algorithm 282, 283, 285  
hexoses 9  
hidden Markov models (HMMs) 277, 278, 286, 293, 294  
high hydrophobicities 111  
high licensing fees 431  
high protein binding capacity 111  
high-performance liquid chromatography (HPLC) 106, 109, 118, 133, 265  
high-risk investments 455  
high-scoring segment pairs (HSPs) 281  
high-throughput screening 179, 302, 316, 399, 414  
high-throughput sequencing (HTS) 153, 217, 222, 278, 333, 337, 389  
highly conserved sequence 296  
highly repetitive DNA 66  
Hill equation 248, 250, 252, 255  
His tag 114, 172, 175, 176, 349  
histamine 92  
histone(s) 27, 42, 68–70, 78, 79, 87, 121, 187, 223, 230, 242, 267, 291, 293, 329  
histone proteins 27, 68, 70, 87, 223, 230, 267  
Hoechst 191, 192, 445  
Hoechst 33258 191  
Hoechst 33342 191  
Hoffmann-La Roche 414  
homogenous assays 303  
homologous recombination 73, 164, 165, 177, 178, 364–366, 376, 378, 382  
homoplastomic 382  
*Homo sapiens* 95, 96, 217, 225  
homozygote character 75  
homozygous 165, 324, 326, 335, 363–365, 389, 390  
for the gene defect 324  
horizontal gene transfer 55, 66, 225, 385  
hormone receptors 22, 113, 274  
host organism 113, 160, 163, 168–169, 171–179, 326, 385, 398, 414  
hot spot 67, 227  
hot start PCR 148–149  
human artifacts 429  
human being, commodity 429  
human dignity 429–430, 433  
human epidermal growth factor 2 (HER2) 218, 225, 268, 300, 313, 354, 421  
Human Genome Project 63, 217, 296, 298, 328, 422  
human immunodeficiency virus (HIV) 21, 56, 168, 268, 326, 363, 415, 437  
HIV-1 168  
human ingenuity 427–429  
human papilloma virus (HPV) 56, 228, 327  
humanized monoclonal antibodies 313  
hyaluronic acid 12  
hybrid promoters 163  
hybridization  
analytical techniques 138–140  
kinetic and thermodynamic control 137–138  
significance of base pairing 137  
hybridization probes 138  
hybridoma cells 315  
hydrogen and salt bridges 263  
hydrogen bonds 19–21, 23, 27, 28, 134, 137, 264, 269, 270, 278, 306  
hydrophilic and polar hormones 37  
hydrophilic structural element 13, 20, 69, 282, 377  
hydrophilic surfaces 109  
hydrophobic 19, 20, 33, 91, 108, 109, 111, 124, 129, 130, 133, 263, 264, 266, 270, 280, 295, 349, 351  
hydrophobic attractions 19  
hydrophobic interaction(s) 33, 109, 111, 263, 264, 266, 270  
hydrophobic interaction chromatography 109, 111  
hydrophobic surface 109, 111  
hydrophobicity 111, 124, 280, 295, 349  
hydrophobicity diagram 280  
hydroxyapatite 112, 133

- 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase 300
- hygromycin 166, 178, 384
- hygromycin phosphotransferase (*hpt*) 384
- hypercholesterolemia 324, 325
- hyperglycosylation 176
- hyperphage 346, 347
- hypertrophic cardiomyopathy (HCM) 324
- hypervariable regions 339
- i**
- ideal genome 219
- identical chromatids 70, 71
- illumina paired-end sequencing 218
- illumina sequencing system 155–156
- imidazole 114–115
- immobilized metal ion affinity chromatography (IMAC) 124, 172
- immune cell recruiting 354
- immune checkpoint inhibitors 353
- immune library 342
- immune system 37, 56, 93, 268, 301, 326, 339, 342, 346, 349–351, 353–354, 418–419
- Immunex Genentech 450
- immuno-RNases 353
- immunocytokines 353
- immunoliposomes 315, 353
- immunotoxins 313, 347, 353
- importins 88
- in situ* hybridization (ISH) 139–140
- in situ* sequencing 222
- inactive ester 317
- inbreeding 364
- inclusion bodies 175
- inclusion volume 110
- incorporation and expression of foreign genes in plants 378
- indels 292
- indirect infringement 427
- individual therapies 326
- indole acetamide hydrolase 385
- indomethacin 317
- inducible promoters 164, 167, 175, 176, 179, 346, 377, 386
- industrial-scale production of recombinant proteins 176
- infectious diseases 55, 326, 342, 393, 445
- inflammatory response 60
- informed consent 294, 430
- inheritance pattern 323, 324, 390
- inherited genetic defects (inherited diseases) 418
- inhibitors 21, 23–24, 46, 105–106, 188–190, 195, 248, 263–264, 266–267, 274, 292, 299, 302–303, 318, 353–354, 408, 413
- initial public offering (IPO) 448, 455
- initiation factors (eIF-2) 83
- initiator caspases 60–61
- INK4-family (inhibitors of kinase) 188
- innate and an adaptive immune system 56
- inorganic ions 9, 23, 34–35, 42
- inositol-1,4,5-triphosphate (IP<sub>3</sub>) 14, 38
- input traits 376, 423
- insect 12, 42, 66, 105, 163–165, 171, 179, 219, 376, 382, 385, 415, 423
- cell system 177–178
- insert 159–161, 181, 274, 281, 315, 342, 355
- cloning 159
- inside-out configuration 183
- Institut Pasteur 445
- institutional investors 448, 455
- institutional review board 294
- insulin 92, 261, 268, 300, 393, 414, 447–450
- intact protein analysis 119–121
- intangible things 425
- integrase 162–163, 386
- integration host factor (IHF) 162–163
- intellectual property 425, 427–428, 430
- treaties 428
- intelligent design 283
- interacting proteins 262–266, 268
- Interactive Tree Of Life (iTOL) 3
- intercalation of EtBr 130
- interference 29, 159, 184, 204, 206, 211, 248, 302, 370, 377, 415
- interference contrast 192, 202
- interferon- $\gamma$  300
- intermediary filaments 50
- intermediates and specialty chemicals 399
- internal ribosome entry site (IRES) 167
- International Cancer Genome Consortium (ICGC) 226–228
- International Patent Law 428
- International Regulatory Harmonization (ICH) 441–442
- interphase nucleus 69
- intervening sequences 79
- intracellular antibodies 356–357
- intracellular organelles 211
- intracellular receptors 17, 37
- intrinsic (mitochondrial pathway) 61
- introns 45, 66, 75, 78–80, 177, 219–220, 278, 286–287, 327–328, 363, 368, 377, 380–381
- inventors, patent application 426
- inverted repeats (IRs) 67
- investigational new drug (IND) 307, 440, 453
- application 440
- status 307
- investor relations (IR) 459, 461–462
- departments 459
- in vitro* recombination of DNA 414
- in vitro* transcription 162, 180
- in vitro* translation 162, 171, 179–180, 348
- ion channel(s) 34–38, 40, 181–185, 211, 295, 302–303, 371–372
- ion channel-linked receptors 37
- ion exchange 111–113, 133, 349
- ion exchange chromatography 111, 133
- ion pumps 35, 36
- ion torrent sequencing system 156, 157
- ionic bonds (electrostatic attraction) 19
- IRES vectors 167
- isoelectric focusing (IEF) 108
- isoelectric point 107, 108, 111, 112

- isolation of specific and high-affinity antibody fragments 347  
 issue price 455
- j**  
 Jackson laboratory 362  
 Jukes–Cantor model 283–285
- k**  
*Kan<sup>r</sup>* codes for phosphorylating enzyme 162  
 kanamycin 162, 163, 378, 384  
   resistance gene 163, 378  
 karyokinesis 188  
 ketoses 9  
 Khorana 447  
 kidney filtration 350, 354  
 Kimura hypothesis 284  
 Kimura model 284  
 kinase domain 22, 261, 262  
 kinase insert domain-containing receptor (KDR) receptor 315  
 kinase-inhibiting proteins 188  
 kinase-mediated phosphorylation 248  
 kinetochore microtubules 70  
 kinetochores 70  
 Kirchhof law, electric circuits 247  
 knock-in mice 361, 364–367, 370  
 knock-out (-in) mice 364–366  
 knock-out mice 226, 342, 361, 364, 366–367, 371  
 knock-out mutants 244  
 knockout RNAi 63  
 Kohonen networks 289  
 Kpn 67  
 Krebs cycle 44  
 Kyoto Encyclopedia of Genes and Genomes (KEGG) 241, 279  
 Kyte–Doolittle plot 280–281
- l**  
 label-free protein quantification 121  
 Lac (lactose) operon 163  
 Lac operator 163  
*Lac* operon 76  
 Lac1 repressor 163  
 lack of stability 313, 399  
 $\beta$ -lactam amidohydrolase ( $\beta$ -lactamase) 162  
 $\beta$ -lactam antibiotics 317  
 $\beta$ -lactamases 55, 162  
*lacZ* gene 163  
 lagging strand 71  
 lambda ( $\lambda$ ) phage 160  
 laser  
   development 209–210  
   in medical technology and biotechnology products 213  
   laser scanning microscopy 211–212  
   microdissection and therapy 212–213  
   optical tweezers 212  
   properties 210–211  
   types and setups 210  
 laser scanning confocal microscopes 211  
 laser scanning cytometry 187, 193–194  
 laser scanning microscopy 191, 195, 197, 211–212  
 late endosomes 92  
 law of *omnis cellula e cellula* 3  
 laws of nature or natural phenomena 427  
 L-dopa 317  
 lead structures 302–303, 305–306  
 leading strand 71, 73  
 least absolute shrinkage and selection operator (LASSO) 242  
 lectins 112–113, 313  
 left border (LB) sequences 379  
 length heterogeneity 336  
 length polymorphism by PCR-fragment size 335  
 lentiviral vectors 363, 369  
 lentiviruses 168, 363, 369–370  
 leptotene 70  
 lethal factor 55  
 leukotrienes 14  
 Levenberg–Marquardt 253  
 licenses 294, 308, 414, 425–426, 431, 440, 451, 459–461  
 licensing deal 460–461  
 lifetime of the donor 207  
 ligand-gated channel 35  
 ligands 22, 24, 34, 35, 37, 61, 248, 250, 254–256, 258, 268, 269, 273–274, 295, 296, 300, 302, 304–305, 313, 324, 353, 355, 372  
 ligands or antibodies 313  
 ligases 71–73, 113, 142, 159, 161–162, 195, 265, 447  
 light 209  
   and heavy antibody chains 339  
   waves 209  
 light amplification by stimulated emission of radiation (LASER) 210  
 light microscopy 201–202  
   confocal microscopy 202–203  
   deconvolution 202  
   fluorescence 203  
   nanoscopy 203–204  
 lignin 12  
 likelihood function 285  
 linear amplification 330–332  
   reactions 153, 333  
 linear discriminant analysis (LDA) 289–290  
 linear double helix 67  
 linear regression function 242  
 Linkage analysis 299, 325  
 linkers 142, 206, 348, 352–354  
 lipases 17, 42, 50, 396, 400–401, 417, 424  
 lipid bilayer 13–14, 34, 181, 200, 208  
 lipids 9, 13–17, 33–35, 41–42, 49–51, 93, 117, 131, 169, 181–182, 200, 280, 295, 312–313, 317, 388, 429  
 Lipinski’s famous “rule of five” 306  
 lipophilic compounds 43  
 lipophilic hormones 37  
 lipophilic structural element 13  
 lipophilicity 111  
 lipopolysaccharide 54  
 lipoproteins 17, 93, 113, 300, 315, 324, 417  
 liposomal carrier systems 315  
 liposomal transfection 169  
 liposome(s) 33–34, 42, 169, 177, 179, 183, 311–312, 315–316  
 liposome-mediated transfection 177  
 liquidation preferences 456  
 lithium acetate-mediated transformation 169  
 lithium chloride 131  
 livestock breeding 423  
 living-color proteins 167  
 lncRNA 29, 75, 79, 222  
 local alignments 282

- lock-and key principle 22, 23
- log odds scores 284, 285
- long interspersed elements (LINEs) 67
- long noncoding RNAs 29, 292
- long tags 172
- long terminal repeats (LTRs) 67, 168, 362, 369
- loop structures 29
- loops 20, 29, 82–83, 239, 247, 252, 254, 255, 263, 272–273, 339–340
- loss of heterozygosity (LOH) 219
- low amount of protein 107
- low copy vectors 162
- low coupling efficiency 315
- low hydrophobicity 111
- low therapeutic index 315
- low-density lipoprotein (LDL) particles 93
- low-density lipoprotein receptor (LDL-R) 93, 300, 315–316, 324
- low-molecular-weight components 9
- low-molecular-weight compounds 55, 171, 295–296, 299, 302, 313, 441
- lymphocyte lysis 313
- lysosomal proteins 92
- lysosomes 42, 45, 87, 92–93, 354
- lysozyme 106
  
- m**
- machine learning technique 243–244, 247, 277, 289
- macro- and micronutrients 387
- macromolecules 5, 9–32, 42, 50, 63–85, 87, 112, 129, 133–134, 201, 203, 250
- MACS2 293
- magic bullet 311, 445
- magnetically controlled targeting 312
- magnetogenetics 372–373
- Mahalanobis distance 288–289
- mammalian artificial chromosomes (MACs) 160
- mammalian cells 34, 72–73, 82, 105, 164–167, 169, 171, 176–177, 183, 188, 193, 195, 222, 228, 274, 329, 342, 348–349, 353, 384, 388
- display 348
- protein expression 178–179
- Manhattan distance 288
- mannose phosphate isomerase system 385, 386
- mannose residues 92
- mannose-6-phosphate residues 92, 385
- MAPK kinase (MKK) 250
- MAPK signaling pathway 248, 251, 252
- mapping 291–294, 375
- marker-assisted (smart) breeding 390
- marker-free plants 385–386
- market penetration 460
- market potential 454–455, 460
- marketable commodities 429
- marketing 454
  - business development 459
  - contacting potential partners 459
  - fee-for-service deals 460
  - market analysis 459
  - market research 459
  - milestone/license fees 460–461
  - PR and IR 461
  - product 459
  - R&D companies 459
  - strategic alliances 460
  - technology transfer or licensing deals 460
  - watching competitors 459
- Mascot 121, 125
- mass action law 264
- mass spectrometer (MS/MS) 117–119, 121–122, 287
- mass spectrometry (MS) 287
  - instrumental setup 118
  - intact protein analysis 119–121
  - microbial identification and resistance detection 125
  - posttranslational modifications (PTMs) 124–125
  - principles of 117–118
  - protein and proteome quantification 121–123
  - protein-protein interaction analysis 123–124
- massive parallel sequencing (MPS) 63, 153
- material transfer agreements (MTAs) 431
- maternal inheritance 382
- mating type  $\alpha$  (MAT $\alpha$ ) 190, 191
- matrix-assisted laser desorption mass spectrometry (MALDI-MS) 117, 287
- matrix-bound lectins 112
- maximum likelihood (ML) 253, 277, 285
  - principle 285
- maximum parsimony (MP) 285
- measure of similarity 281
- mechanical lysis 106
- mechanically gated channel 35
- mechanism of glutamate overproduction 406–407
- medical context 151
- medicinal therapeutics 384
- MEDLINE 279
- MEGA phylogeny program 285
- meiogametes 70
- meiosis 67, 69–71, 380
- meiosis II 70
- meiospores 70
- meiotic recombination 67
- meiotic segregation 386
- melting temperature ( $T_m$ ) 28, 137, 213
- membrane bilayers 33
- membrane lipids 9, 13–17, 93
- membrane permeability 33–34
- membrane potential 35, 37, 181, 183
- membrane proteins 13–14, 17, 21, 33–34, 36, 41, 54, 89–92, 108, 111, 348, 369
- membrane receptors 37, 239, 295
- membrane voltage 182
- membrane-transporting sequences (MTS) 357
- 2-mercaptoethanol 105, 107
- merger/takeover alliances 461
- meristem 57, 385, 388
- messenger RNA 29, 221, 269, 272
- metabolic engineering 403–405
- metabolic network 239–240, 243–244, 247, 404
- metabolic process 54, 241, 279, 423
- metabolite-based representation 240
- metagenome 398
- metaphase 51, 69–70, 188
- metaphase I 70
- metaphase II 70
- methanol 108, 164, 176, 210



- methicillin resistant *S. aureus* (MRSA) 55, 85  
 methionine 19, 81, 83, 402, 407–408, 410  
 [35S]methionine 180  
 methionine sulfoxide-resistant strains 410  
 methionine tRNA 83  
 methodological tools of modern biology 7–8  
 methyl transferases 81  
 N<sup>6</sup>-methyladenine 80  
 methylate DNA 142  
 methylation 69, 72, 78, 81, 141–143, 223, 227, 242, 283, 291, 330  
   of cytosine 80, 293  
   of promoters 390  
 5-methylcytosine 72, 80, 83, 330  
 methyl dopa 317–318  
 methyltransferases 141–143, 223  
 MGI laboratories 362, 363  
 Michaelis–Menten constant 249, 251  
   equation 249–250  
   kinetics 248, 250–251  
 microarray(s) 149, 223, 225, 227, 240–241, 287–290, 292–294, 333–334–335, 414, 422  
   data 277, 279, 294  
 microarray gene expression markup language (MAGE-ML) 279  
 microbial identification and resistance detection 125  
 microbial infection diagnosis 327  
 microbiome 55, 224, 228  
 microbiota 55  
 microcalorimetry 266  
 micrococcal nuclease 180  
 micromanipulators 181–182, 364  
 microorganisms 12, 42, 55, 93, 125, 141, 148, 175, 244, 295, 297, 323, 326–327, 332, 334, 393, 395, 397–398, 400, 402–406, 408, 413  
 micro-RNAs (miRNA) 29, 65, 75, 79, 149, 152, 222, 242, 278, 292, 331  
 microsatellite(s) 67, 220  
   DNA 66–67  
   PCR 67, 421  
 microscopy in the living cell analysis of fluorescently labeled proteins in vivo 205–206  
 antibodies 205  
 enzymes 204  
 Förster resonance energy transfer (FRET) 207  
 fluorescence correlation spectroscopy (FCS) 206–207  
 fluorescence recovery after photobleaching (FRAP) 206  
 single-chain antibodies 205  
 single-molecule fluorescence 207  
 microtubules 50–53, 68–70, 188, 261  
 middle repetitive DNA 66  
 milestone payments 460  
 mineral corticoids 17  
 miniature chips 337  
 minibodies 352  
 minimal information about a microarray experiment (MIAME) 279  
 minimal media 165, 176  
 minisatellite 66, 67  
   DNA 67  
 minisequencing 336  
 mitochondria 13, 25, 43–50, 66, 81–82, 87–89, 95, 254–255, 379  
 mitochondrial genome (mtDNA) 44–46, 81, 379  
 mitogen-activated protein kinase (MAPK) cascade 248, 250–252  
 mitosis 69–72, 193  
   M phase 187–188  
 mitotic cell division 69, 187  
 mixtures of alcohol and water 129  
 M-MuLV reverse transcriptase 144  
 mobile genetic elements 67  
 mobile nuclear import receptors (importins) 88  
 model organisms 95–98, 100, 123, 177, 187, 262, 272, 284, 287, 298  
 modular construction of the antibody 339  
 molecular beacons 331–333  
 molecular biology techniques 375  
 molecular biotechnology in Europe 424  
   foundations of 413–414  
   green biotechnology  
     agriculture and food production 422  
     functional food 423  
     genomic approaches in 423  
     livestock breeding 423  
     transgenic plants 422–423  
   red biotechnology  
     biopharmaceutical drug development 414–416  
     white biotechnology 424  
 molecular cell biology 95  
 molecular clock 284  
 molecular cloning 147, 153  
 molecular diagnostics, medicine  
   chromosomes by recombination 329  
   deletion/duplication of genes 328–329  
   DNA/RNA purification 331  
   epigenetic changes 329–330  
   forensics 325  
   functional classification 327  
   goals of 330  
   HLA gene 325  
   insertion or deletion 328  
   microbial diagnosis 327  
   molecular genetic differences 327  
   monogenic diseases 323–325  
   nucleic acid analysis 330  
   nucleic acids 331–332  
   nucleotide repeats 328  
   pharmacogenomics 325–326  
   point mutations 327–328  
   polygenic diseases 323–325  
   resistance diagnosis 327  
   sequence analysis 330  
   structural classification 327  
   susceptibility to infectious diseases 326  
   target sequence and known sequence variations  
     fragment length analysis 335–336  
     nucleic acid microarrays 333–334  
     nucleic acid tests 331–332  
     production and manufacture of microarrays 334–335  
     quantitative PCR 332–333  
     viral diagnosis 326–327  
 molecular display methods 348

- molecular genetic detection  
  methods 327
- molecular genetic differences 327
- molecular pharming 423
- molecular recognition process 18,  
  22, 27
- molecular sieving 108
- molecular switches 24, 40
- molecular target 298, 302
- molecularly defined channel proteins  
  183
- Moloney murine leukemia virus  
  (M-MuLV) 144, 168
- monoclonal antibodies 112, 119,  
  171, 223, 313, 315, 339, 343,  
  350, 356–357, 415–416, 450
- monogenic diseases 226, 299, 323,  
  419
- monoisotopic peak pattern 117
- monomeric building blocks 9
- monosaccharides 9
- monosodium glutamate (MSG)  
  393, 406
- monovalent display 347
- morula 362, 364
- morulae 364–366
- mosaic genes 79
- motif databases 278
- motor proteins 212
- mouse (*Mus musculus*) 95, 298
- M phase 72, 187–189, 191–192,  
  195
- mRNA  
  display 348  
  enrichment 131  
  fragments 287
- MTEV/dCHIP 294
- multi-ion system 182
- multicellular organisms 5, 37, 56,  
  57, 63, 123, 188
- multidimensional scaling (MDS)  
  289
- multidrug resistance proteins 35
- multidrug resistant pathogens  
  (MDR) 85
- multienzyme complexes 24, 52, 72,  
  76, 80–81, 89
- multiparameter optimization 306
- multiple alignment 281–283
- multiple cloning site (MCS) 160,  
  162, 166–168, 174, 380
- multiple resistance-associated  
  protein (MRP) 36
- multiplexing 122, 220, 333–334
- multitude of genes 333
- multivalent display 346–347
- mung bean nuclease 144
- murein sacculus 52, 54
- muscarinic receptor (mAChR) 37
- Mus musculus* 95, 298
- mutagens 72, 403
- mutation(s) 300, 325  
  and repair mechanisms 72  
  and selection 261, 402–403, 410
- mutation-inducing chemicals 403
- mutationally separated (MS)-PCR  
  336
- mutual information 289
- Mycobacterium tuberculosis* 273,  
  274, 406
- myelin sheaths 14
- myocardial infarction 93, 324
- n**
- NADH 43, 50, 318, 405
- naïve antibody gene library 342
- Na<sup>+</sup>, K<sup>+</sup>-ATPase 35, 42, 43
- naked DNA 169, 382
- nanopore sequencing 157–158
- native gel electrophoresis 107, 108
- natural feedback inhibitors 408
- natural isotope pattern 117, 118
- natural products 302
- NCBI Genome database 217
- ncRNA-DB 278
- N-/C-terminal peptide sequences  
  (tags) 164
- NCT MASTER program 229
- necrosis 60, 61, 230, 268, 300, 352
- Needleman–Wunsch algorithm  
  282
- negative regulatory protein Tet  
  repressor (TetR) 166
- negative selection marker systems  
  384–385
- negative selection markers  
  383–385
- neighbor joining (NJ) 285
- neighboring thymine 72
- nematode (*Caenorhabditis elegans*)  
  95, 123, 217, 286, 298
- Neo-Darwinian Synthesis 283
- neomycin 365, 384  
  resistance 365
- neomycin phosphotransferase II  
  (*nptII*) 384
- neural networks 277, 286, 290
- neuronal signal transduction 37, 55
- neurotransmitters 37, 318, 427
- neurovesicles 92
- new blood vessels 315
- new drug application (NDA) 440,  
  442
- new innovations 449
- New Delhi metallo-β-lactamase 1  
  (*NDM-1*) 55
- next generation sequencing (NGS)  
  6, 55, 63, 149, 153, 220, 223,  
  226, 229, 277, 281, 291, 333,  
  335, 337, 376, 390
- NF-κB signalling pathway 267, 268
- Ni affinity 349
- nicotinic acetylcholine receptor  
  (nAChR) 37
- nidation 364
- Nigosine 108
- NIH Roadmap 293
- nitric oxide 38
- nitrocellulose membranes 135, 138
- nanopore technologies 157, 218
- N*-methyl-d-aspartic acid (NMDA)  
  receptors 37, 363, 371
- NO synthases (NOS) 38
- non-cleavable linkers 354
- non-coding lncRNAs 222
- non-homologous end joining (NHEJ)  
  378
- noncoding 29, 65, 75, 76, 78–80,  
  131, 220, 222, 226, 278, 285,  
  286, 292, 296, 325, 328, 410
- noncoding RNA (ncRNA) 29, 76,  
  79, 278, 292
- noncovalent bond 19–23, 27
- nonfamilial diseases 299
- nonpolar organic solvents 396,  
  399–400
- nonpolyadenylated RNA 131
- nonsense mutations 66
- nonsteroidal anti-inflammatory  
  drugs (NSAIDs) 15
- norethisterone 318
- Northern blotting 137, 138
- Northern hybridization 388, 389
- novel biocatalysts 397, 398
- Noxa 61, 325
- N-terminal His<sub>6</sub> tag 115
- N-terminus peptid sequence 119,  
  205
- nuclear import receptor complex  
  88

- nuclear magnetic resonance spectroscopy (NMR) 21, 171, 176, 266, 278
- nuclear pore complexes (NPCs) 42, 78, 80, 87, 88
- nuclear receptors 295, 296, 298, 304
- nuclease BAL-31 144
- nucleases 42, 68, 72, 129, 141–144, 159, 223, 274, 361, 366, 376–379
- nucleic acid(s) 9, 25  
as active agents 300–301  
microarrays 333–334  
separation 133
- nucleic acids tests  
digital quantitative PCR 331  
linear amplification 331  
polymerase chain reaction (PCR) 331  
quantitative PCR 331–333  
quantitative PCR with internal gene probes 331
- nucleoid 54
- nucleolus 42, 70, 83, 87
- nucleoporins 87, 88
- nucleoside diphosphate kinases (NDPKs) 114
- nucleosides 25, 231
- nucleosomes 42, 68, 70, 223, 230, 291, 293
- nucleotide(s) 3, 9, 25–32, 63, 66–67, 69, 72–75, 81–83, 95, 112, 114, 134–135, 141, 143–144, 148–149, 151–157, 164, 166, 180, 219–220, 222–225, 239, 261, 269, 281, 283, 291–293, 299, 327–330, 332–333, 335–337, 361, 366–367, 375, 378, 406, 429  
deamination 72
- number of insertions, DNA via PCR methods 388
- nutraceuticals 376, 423
- N50 value 292
- nylon 135, 138
- O**
- O-GlcNAc-modified peptides 124
- Okazaki fragments 71
- oligo(dT) 131
- oligosaccharides 9, 14, 19, 91, 320  
residue 19, 91
- oncogenes 56, 220, 225, 227, 325, 327–330, 379
- oncology 191, 228–231, 292, 421, 450
- oncoprotein Src 261, 262
- “one gene, one protein” hypothesis 75
- Online Mendelian Inheritance in Man (OMIM) 279
- oocyte(s) 69, 183–184, 362–364
- open reading frame 164, 221, 244, 356, 363, 409
- operational amplifier 182
- operons 76, 78–79, 163, 166, 407–408
- opsonization 312
- optical tweezers 211–212
- optimal algorithms 282
- optimal selection marker system 383–384
- optimal/heuristic 282
- optimized by strain development 403
- ordinary differential equation (ODE) models 247, 252
- organelle 13, 42–43, 46, 48–49, 52, 54, 87, 89, 129–130, 201, 211–212, 217, 228, 382, 429
- origin of replication 72–73, 162
- outcrossing of traits 382
- output traits 376, 423
- outside-out configuration 183–184
- (over)expression of recombinant proteins 105
- oviduct flushing 363
- OXA complex 89–90
- oxalacetate 407, 409
- oxidation 44, 50, 72–75  
and methylation 72
- $\beta$ -oxidation 44, 50, 89
- P**
- pachytene 70
- packaging cell line 167–168
- Paediatric Committee (PDCO) 436
- pairwise alignment 281–282, 291
- palindromes 141
- PAM score matrices 281
- pancreas trypsin inhibitor 264
- panel sequencing 220–221, 292
- panning 346–348, 350
- paracrine signals 37–38
- paracrystalline structures 14
- parallel chain 20
- paratope 339–340, 350, 356
- paromomycin 384
- partition chromatography 133
- partition coefficient 110
- passenger mutations 226–227, 299
- passive targeting 311–313
- pasteurization 413
- patch clamp method  
applications 183–185  
configuration 182–183  
ion channels 181  
technical requirements 181–182
- Patent and Trademark Office (PTO) 426–427
- patent bargain 425
- patent thicket 431
- patents  
application 426  
in biotechnology 428  
block technological development 425  
DNA and proteins 427  
human ingenuity 427  
on improvements 426  
infringement 427–428  
intellectual property 425  
International Patent Law 428  
organic compounds 427  
in pharmaceutical and molecular biotechnology 427  
on products 426  
prosecuting 426  
term of 425  
in United States 426
- patents on processes 426
- pathogenic bacteria 55, 273–274
- pathogens 29, 55, 56, 85, 96, 228, 296, 326–327, 339, 342, 349–350, 375, 379, 385, 414
- pathogens/abnormal molecules 339
- pattern of proteins 313
- PAUP phylogeny program 285
- pBR322 159, 380
- pBR322-ori 162
- PCR reaction efficiency 149
- PCR-based methods 337
- P1-derived artificial chromosomes (PACs) 160
- pectin 12, 53
- penicillin(s) 52, 162, 302, 393, 403, 406–407, 409, 413, 445  
biosynthesis 409
- pentoses 9, 11, 25–26, 406

- peptide bonds 17, 19–21, 29, 119, 121, 165, 264
- peptide hormones 92, 261, 268
- peptidoglycan cell wall 52, 54, 106
- percent accepted mutation (PAM) 203, 281, 284–285
- percent expected mutation (PEM) 284–285
- periplasmic space 54, 340, 346
- permeability barriers 33
- permission of the patent holder 427
- peroxins 89
- peroxisomes 43, 87–89
- personalized medicine 337, 350, 355, 414, 421
- P-glycoprotein (P-gp) 35–36
- pH 23, 42, 45, 105–109, 111–112, 114–115, 129, 176–177, 311–312, 317, 399
- phage display
  - antibody gene library 341–342
  - definition 346
  - disadvantages 356
  - genetic diversity 340
  - helper phage 346
  - in vitro* selection of antibodies 357
  - M13K07/Hyperphage 347
  - scFv/Fab molecules 346
- phage vectors 160
- phagemids 161, 341, 346–347
- phages 55–56, 162–163, 199, 378
- phagocytosis 47–49, 60, 93, 350
- phagosomes 42
- pharmaceutical and biomedical products 427
- pharmaceutical and biotechnological processes 427
- pharmaceutical form 306, 311
- Pharmaceutical Research and Manufacturers of America (PhRMA) 415–416
- pharmacodynamics 306, 326, 441
- pharmacogenetics 139, 421
- pharmacogenomics 325–326, 414, 421
- pharmacokinetic properties 176, 306, 316, 352
- pharmacokinetics 36, 306, 326, 352, 354
- pharmacologically selective effector molecules (PSAMs-PSEMs) 372
- pharmacotherapy 445
- pharmacovigilance 307, 436
- Pharmacovigilance Risk Assessment Committee (PRAC) 436
- phase contrast microscopy 201, 202
- phase I 307
- phase II 307
- phase III 307
- phase IV 307, 308
- phenytoin 316, 317
- Philadelphia chromosome 227, 329
- phleomycin 384
- phosphatases 25, 145, 268
- phosphatidylcholine 14, 15, 35
- phosphatidylinositol 14, 15, 35, 38
- phosphatidylserine 15, 33, 35
- phosphodiesterase 37, 41, 43
- phosphoglycerate (PG) 47, 48, 245
- phospholipase A<sub>1</sub> 14
- phospholipase A<sub>2</sub> 14, 15, 17
- phospholipase C 14, 38, 42, 43
- phospholipases 14, 37, 42, 45
- phospholipids 9, 10, 13–15, 17, 21, 33, 34, 312
- phosphoproteins 112
- phosphorylation 20, 24, 25, 40, 49, 52, 69, 124, 188, 248, 251, 252, 267, 268, 272, 384
- phosphotyrosine 38, 261
- photolyases 73
- photosynthesis 6, 10, 47
- PHYLLIP phylogeny program 285
- phylogenetic profiles 266
- phylogenetic tree 3, 96, 283, 285
- phylogeny 3, 48, 98, 100, 101, 285
- phylogeny of land plants 98
- physical drug targeting 312
- phytofarming 382
- phytopharming 376, 423
- Pichia pastoris* 164, 171, 175, 399
- pili 54
- pinching off of vesicles 92
- pinocytosis 93
- piRNA 10, 29, 292
- pivampicillin 317
- piwi-interacting RNAs 29
- placenta 366
- plant biotechnology
  - challenges in 376
  - crop plants 375
  - definition 375
  - gene expression control 377
  - genetically engineered plants
    - DNA and RNA verification 388–389
    - genetic maps 390
    - molecular markers 390
    - protein analysis 389
    - stability of transgenic plants 390
- genetically modified organisms (GMOs) 375
- genome editing 377–378
- input traits 376
- output traits 376
- plant breeding 375
- regeneration of transgenic plants
  - composition 387–388
  - procedures 387
- transformed cells
  - antibiotic resistance genes 385
  - consumer acceptance 385
  - horizontal gene transfer 385
  - marker-free plants 386
  - negative selection marker systems 384–385
  - optimal selection marker system 384
  - positive selection marker systems 385
  - selectable markers 383
- transgenic plants production
  - Agrobacterium*, natural transformation system 379–381
  - biolistic method 381–382
  - plastid transformation 382
  - stable/transient transformation 379
  - viral expression systems 382
- plant breeding 375, 423
- plant cells 3, 6, 10, 12, 42, 45, 47, 48, 53, 58, 130, 375, 378–380, 382–387
- plant genetic systems (PGS) 449
- plant mesophyll cell 4
- plant mitochondria 45, 81, 379
- plaque purification 177
- plasmids 5, 54, 130, 138, 145, 152, 159–162, 164, 179, 217, 361, 367
- DNA 130, 134, 143, 368–369
- plastid(s) 5, 13, 50, 87, 88, 382
- plastid genomes 379, 382
- plastid transformation 382

- point mutations 22, 67, 72–75, 283, 327–329, 335, 337, 365, 403, 410
- point of care diagnostics (POC) 333, 337
- polar environments 111
- polar microtubules 70
- polar secondary compounds 43
- polarsignaling molecules 37
- polarizer 202
- poly(A) polymerase 80, 166
- poly A tail 29, 66, 78, 80
- poly(butylcyanoacrylate) nanoparticles 316
- poly(CA) 67
- poly(dT) 133
- poly His-tag 349
- polyacrylamide gel 134, 135, 149, 389
- polyacrylamide gel electrophoresis (PAGE) 135
- polyadenylated RNA 131
- polyadenylation 5, 131, 166, 221, 328, 368
- polyamines 27, 388
- polyclonal antibodies 339, 350
- polyethylene glycol (PEG) 169, 312, 315, 354
- polygenic causes of common diseases 299
- polygenic diseases 323–325
- polyhedrin(P<sub>PH</sub>) 177
- polyhedrin-rich occlusion bodies 177
- polyhistidine tag 113
- polyhistidine-containing proteins 113
- polylinkers 160, 162
- polymer nanoparticles 316
- 5'-polymerase activity 143
- polymerase chain reaction (PCR) 67, 137, 144, 147–152, 161, 326, 331, 364, 399, 414
- basic principle 147–148
- cloning techniques 152
- digital 151
- gene expression studies 152
- genome analysis 151–152
- multiplex 149
- phases and efficiency 149–150
- primer design and hot start 148–149
- qualitative analysis 149
- reverse transcription 149
- polymers 12, 17, 51, 109, 117, 169, 311, 320
- polypeptides 17–21, 81, 89, 107, 108, 280
- polyribosome 83
- polysaccharides 5, 9–13, 42, 49–52, 54, 96, 134, 354, 394
- polytene chromosomes 219
- population sequencing 226
- porin 52, 54
- porous materials 109
- positive selection markers 383, 385
- posttranslational modifications (PTMs) 19, 41, 87, 124, 267
- posttranslationally modified recombinant proteins 171
- potential immunogenic reactions 176
- potential targets 243, 296–297, 313
- Potter–Elvehjem homogenizers 106
- p10 promoters 177
- preclinical trials 306, 307, 362, 370
- precursor proteins 88–90, 370
- prerequisite of novelty 301
- press releases 231, 462
- presynapse 92
- prezygotes 363
- primary cell cultures 179
- primary protein structure 21
- primary recovery 349
- principal component analysis (PCA) 222, 289
- principle of antiangiogenesis 315
- principles of vaccination 445
- pro-apoptotic protein 61
- procambium 57, 58
- ProDom 278
- prodrug(s)
- biological membranes 317–318
- definition 316
- drug solubility 316–317
- drug stability 317
- high-throughput screening 316
- polymeric coatings 319
- principle 316
- side effects 320
- prodrug strategy 313, 316, 318
- productive livestock 423
- programmable array microscopes (PAMs) 203
- programmed death receptor 1 (PD-1) 353
- prokaryotes 3, 5, 9, 17, 27, 78, 95, 129, 130, 217, 270, 273, 382
- prokaryotic and eukaryotic ribosomes 82, 84
- prokaryotic cells 3, 4, 274
- prokaryotic expression vector pET15b-RGS16 115
- prokaryotic ribosome 29, 84
- prometaphase 70, 188
- promoters 163, 164, 179
- regions 77
- pronuclear injection 362–364
- proofreading polymerases 152, 161
- property rights 425, 428, 430
- prophage 162
- prophase 69–71, 188
- prosite 278
- prostaglandins 14, 37, 59
- proteases 18, 21, 23, 24, 42, 50, 55, 57, 60, 105, 106, 396
- proteasomal pathway 188
- proteasomes 83, 91, 189, 268
- protein A 81, 109, 112, 178, 349
- protein A/G affinity chromatography 349
- protein and proteome quantification 121–123
- protein biosynthesis 29, 47, 48, 78, 81–85
- protein complexes 42, 70, 71, 80, 105, 124, 177, 205, 223, 261, 262
- protein database (PDB) 119, 262, 263, 278
- protein desorption 112
- protein detection in gels 108
- protein digestion 119
- protein-DNA interactions
- biochemical and biophysical methods 270, 271
- biotechnological applications 274–275
- medical importance of 273–274
- nucleotides 269
- regulatory networks and system biology 270–273
- statistical analyses of 269
- structural classification of 270, 272
- thermodynamic consideration 270
- protein domain 79, 87, 261–263, 278, 353

- protein expression 115, 121, 123, 165, 171–173, 175–177, 179, 349
- protein extract 106–107
- protein families 21, 23, 106
- protein families (Pfam) database 278
- protein fragmentation 119
- protein G 112
- Protein Information Resource (PIR) 278
- protein kinase A 24, 37, 41
- protein kinase C (PKC) 38
- protein kinases 24, 181, 188, 313
- protein knockdown 356
- protein L affinity 349
- protein localization 267, 281
- protein-protein interactions 123, 180, 240
- actin filaments/microtubules 261
  - biotechnological and medical applications of 268
  - Brownian motion 261
  - disadvantageous 268
  - domains 261–262
  - energetics 264
  - fusion proteins 265
  - GST 265
  - hydrophobic interactions 263
  - protein networks and complexes 262
  - regulation of 266–268
  - strong (stable) and weak (transient) interactions 261
  - structural properties of interacting proteins 262–263
  - theoretical prediction of 266
  - thermodynamics 264
- protein purification methods 109
- protein sorting
- Golgi apparatus 92–94
  - import and export via nuclear pore 87–88
  - import in mitochondria, chloroplasts and peroxisomes 88–89
  - important pathways of 87
  - transport into the endoplasmic reticulum 89–92
- protein stability 112, 267
- protein structures 21, 267, 277–279, 399
- protein translocation 87
- protein translocators 87, 89
- protein tyrosine kinase activity 299
- proteins 9, 17, 50
- characterization of 105
  - column chromatography methods 109–114
  - enzymatically active 105
  - extract production 106–107
  - gel electrophoretic separation methods 107–108
  - nucleosidediphosphate kinases (NDPKs) 114
  - protein purification methods 109
  - purification of recombinant His<sub>6</sub>-RGS16 114–115
- proteomics 60, 117–125, 409
- protoderm 57, 58
- proton gradient 43, 46–48
- protoplasts 12, 53, 106, 378, 382
- pseudogenes 65, 66, 296
- pseudotime 294
- P-site 83
- PSORT 281
- ptac promoter 163
- public domain 425, 427
- Public Library of Science (PLOS) 279
- public relations (PR) 458, 459, 461
- PubMed 279
- pUC-ori 162, 178
- pulsed field gel electrophoresis (PFG) 134
- pulsed lasers 210, 211
- Puma 61
- purification of nucleic acids 330, 331
- purification procedure 106, 109, 113, 115
- purine 25, 26, 52, 72, 73, 76, 410
- purine nucleotide-binding proteins 112
- pyrophosphatase 263
- pyrosequencing 153–155, 337
- pyruvate transporter 44
- q**
- QconCat concept 121
- qualitative traits 376
- quality and stability 306
- quanta 209
- quantitative analysis of RNA 144
- quantitative polymerase chain reaction (qPCR) 27, 144, 149–150, 242, 326, 331–333, 335, 376
- with internal gene probes 331
- quantitative trait loci (QTLs) 375
- quantitative traits 376
- Quartet-PUZZLE 285
- quasi-monochromatic 211
- quaternary protein structure 21
- r**
- Rab cascade 92
- Rab proteins 92
- radioactive label 135, 143, 180
- radioimmune conjugate 354
- rafts 17
- Ran-GDP 88
- random mutagenesis 283, 348, 399
- ranitidine (Zantac<sup>®</sup>) 318
- rapid translation system 180
- Ras superfamily 38
- rational design 399
- reach-through licenses 431
- reaction equilibrium 23
- reaction rate 23, 247, 249, 250
- reactive oxygen species (ROS) 73
- reactome 279
- reads 155
- real-time PCR (RT-PCR) 144, 150, 389
- rearrangement of gene fragments 339
- receptor/ligand blockade 350, 355
- receptor-mediated endocytosis 36, 93
- receptors 10, 17, 22, 33, 34, 36–38, 40, 88, 92, 93, 239, 248, 268, 270, 274
- receptor tyrosine kinase (RTK) 38, 43
- recessive monogenic disease 323
- recessive or dominant 363
- recognition signals 87
- recognition sites 141, 142, 162
- recombinant adeno-associated viruses (rAAVs) 369
- recombinant adenoviruses 167, 179
- recombinant antibodies
- advantages of 349–350
  - cell-penetrating antibodies 357
  - formats and applications of bispecific antibodies 354–355

- camelid antibodies and V<sub>H</sub> domains 351
- CAR 355
- Fc engineering 352
- fusion proteins 353
- IgG molecule 352–354
- scFv and dsFv 351–352
- scFv-Fc fusions 352
- future aspects of 355–356
- future protein therapeutics 357
- generation of
  - antibody gene libraries 341–342
  - in vitro* selection systems 342
  - mammalian antibody response 340, 341
  - production and purification of 348–349
  - transgenic mice with human IgG genes 342
  - intracellular antibodies 356–357
  - successful production of 356
- recombinant baculoviruses 177
- recombinant DNA techniques 159, 427, 447
- recombinant methods 313, 415
- recombinant plasmid vector 159
- recombinant production strain 399
- recombinant protein 105, 113, 163, 164, 171
  - cell-free system 179–180
  - E. coli* 172–175
  - insect cell system 177
  - yeasts 175–177
- recombinant viruses 165, 177, 361
- recombination 70
  - elements 162
- reconstructing signaling networks 240
- recycling 42, 92, 350
- red algae 3, 97, 134
- red biotechnology
  - biopharmaceutical drug development
    - advantages of 415
    - diagnostic methods 421
    - first therapeutic antibodies 415
    - gene therapy 416
    - Germany/EU in 2017 414
    - personalized medicine 421
    - pharmacogenomics 421
    - regenerative medicine 420
    - systems biology 422
  - therapeutic antibodies 415
  - therapeutic human proteins 414
  - therapeutic RNAs 417
  - tissue engineering 419–421
- reduced-representation bisulfite sequencing (RRBS) 293
- reduction division 70
- reduction equivalents 43, 44
- reform the patent system 432
- RefSeq database 278
- regenerative medicine 414, 419–421
- regulatorycenter 24
- regulatory DNA 66, 77
- regulatory network 239, 240, 247, 268, 270–273, 279, 291
- regulatory promoter 172
- regulatory proteins 10, 24, 25, 44, 49, 57, 166
- regulatory T cells (T<sub>reg</sub>) 353
- release factor 83
- renaturing protein 20
- repair enzymes 72–74, 81
- repetitive DNA 65–67, 325
- replacement parts 66
- replication bubble 72, 73
- replication fork 71–73
- replication origin 162, 163, 165, 174, 179, 181
- replication region 159
- replication sequences 164, 166
- replicative cell senescence 68
- reporter gene 7, 184, 265, 298, 304, 305, 377
- reporter gene assays 298
- research and development (R&D)
  - companies 459
- research exemption 427, 428, 432
- resistance against antibiotics 334
- respiratory chain 6, 43, 44, 50, 51
- response plasmid 166
- responsive transactivator (rtTA) 256, 257
- restriction digest 143, 160, 161
- restriction endonucleases types 141
- restriction enzymes 7, 67, 113, 134, 138, 141, 159
- restriction fragment length polymorphism (RFLP) 335, 390
- restriction sites 141–143, 152, 160–162, 341
- reticulocyte lysates 171, 179, 180
- reticuloendothelial system (RES) 312
- retinoblastoma (Rb) gene 325
- retroposons 66, 67
- retropseudogenes 66
- retrotransposons 67
- retroviral expression systems 167, 168
- retroviral infection 362–363
- retroviral vector 168, 316, 362, 363
- retroviruses 6, 56, 167
- revenue flows 460
- reverse genetics 7, 361
- reverse tetracycline-controlled transactivator (rtTA) 166
- reverse transcriptase 28, 56, 57, 75, 144, 222
- riboflavin 24, 26, 409, 410
- ribonucleic acid (RNA) 29, 129
  - fragments 138
  - interference 301, 302
  - isolation 131
  - polymerase 75, 76, 163, 262
  - polymerase I 75
  - polymerase II 75, 166
  - polymerase III 75
  - reverse transcriptase 144
  - sequencing 279, 291
    - in situ* sequencing 222
    - RNA-species and modifications 221–222
    - single cells 222
    - tag-*vs.* full-length sequencing 221
    - world 29
- ribonucleotides 29, 125
- ribosomal display 348
- ribosomal proteins 29, 42, 55, 83, 266, 267
- ribosomal RNA (rRNA) 81, 129, 221
- ribosome-binding site (RBS) 163–164, 174
- ribosomes 4–6, 10, 41, 50, 54, 58, 81–84, 87, 89
- ribozymes 10, 29, 32, 80
- ricketts 17
- right border (RB) sequences 379
- ring-shaped DNA (cpDNA) 44, 47, 54, 161
- Ri-plasmid 379

- RISC (RNA-induced silencing complex) complex 29  
 RNAdb 278  
 RNAfam 278  
 RNAi method 29  
 RNA interference (RNAi) 29, 184  
   knock-down 206  
 RNA-seq 77  
 RNA-seq by NGS 60  
 RNases 131, 331  
 RNA-species and modifications 221  
 5.8S rRNA 82  
 18S rRNA 82  
 26S rRNA 82  
 robust and cost-effective testing system 296  
 rough ER 4, 6, 41, 44, 89  
 ruby laser 210  
 Runge–Kutta method 252
- S**
- Saccharomyces cerevisiae*  
 (*S. cerevisiae*) 22, 95,  
 123–124, 160, 164–165, 171,  
 175–176, 187–192, 194, 217,  
 220, 256, 262, 283, 410  
*S*-adenosylmethionine (SAM) 89,  
 142  
 safety and efficacy 307, 439  
 salicylic acid 317  
 salt-induced precipitation 109, 112  
 samtools packages 294  
 Sanger enzymatic sequencing  
   method 153  
 satellite DNA 66, 67, 69  
 scale free networks 243  
 scanning transmission electron  
   microscope (STEM) 198  
 scFv 205, 340, 342, 346–349,  
   351–355  
   format 351  
   scFv-Fc fusions 352  
*Schizosaccharomyces pombe* 164,  
 175–177  
 scientific and technological  
   competence 456  
 scientific excellence 449  
 score matrices 281, 284  
 screening 296, 399, 403  
   of metagenome libraries 398  
 second generation sequencing  
   methods 155  
 second harmonic generation (SHG)  
   212
- second messengers 24, 37, 38, 41  
 second signal sequence 89  
 secondary active transporters 36  
 secondary compounds 42  
 secondary protein structure 21  
 secondary screening 305  
 secondary structure 19, 263  
 secretion, the periplasm 348  
 Seeburg 447  
 selection marker 164, 174, 365,  
   382, 383  
 selection of transformed yeasts 165  
 selectivity of protein transport 87  
 selfish DNA 67  
 semi-synthetic antibody gene  
   libraries 342  
 separation assays 303  
 separation of nucleic acids  
   133–134  
 separation principles in protein  
   purification 107  
 sequence 153, 160  
   of building blocks 280  
   coverage 155  
   depth 155  
   by ligation 337  
   by synthesis 155  
   library 155  
 sequence-specific recombinases  
   386  
 sequence-specific recombination  
   162, 386  
 sequencing projects-human  
   cancer driver mutations  
     226–228  
   direct to consumer testing (DTC)  
     231  
   environments 228  
   ethical consequences 231–232  
   initial sequencing of the human  
     genome 224  
   oncology 228–231  
   population sequencing 226  
   screening for genetic diseases  
     226  
   1000 genomes project 224–225  
 sequencing to characterize  
   chromatin structure, and  
   beyond 223  
 sequential cloning 160  
 Sequest 121  
 serial analysis of gene expression  
   (SAGE) 279, 287
- severe immunodeficiency syndrome  
 (SCID) 326  
 sex chromosomes 68  
 sexual hormones 17  
 SH2-domains 261  
 SH3-domains 261  
 Shine–Dalgarno sequence 163  
*shmoo* phenotype 190, 191  
 short interspersed elements (SINEs)  
   67  
 Short Read Archive (SRA) 279  
 short tags 172  
 short tandem repeats (STRs) 67,  
   325  
 shrimp alkaline phosphatase (SAP)  
   145  
 shuttle principle 176  
 shuttle vector 162, 167, 176–178  
 sialic acid 14  
 sigma factor 5, 76  
 signal patches 87  
 signal peptidases 87, 89–91  
 signal peptides 89–91, 176  
 signal recognition particle (SRP) 89  
 signal sequence analysis 280–281  
 signal sequences 87–91, 280, 281,  
   340  
 signal transduction 10, 14, 35–41,  
   49  
 signaling network 239, 240  
 signaling sequences 48  
 significance of base pairing 137  
 silencer 77, 224  
 silent mutations 75, 327  
 silver stain method 108  
 simulated annealing 253  
 single cell 6, 57, 95, 140, 184, 191,  
   193, 222, 294  
 single cutters 162  
 single nucleotide polymorphisms  
   (SNPs) 75, 224, 299, 328,  
   421  
 single nucleotide variants (SNV)  
   225, 292  
 single organs 380  
 single-cell analysis 294  
 single-cell ATAC-seq 294  
 single-cell RNA sequencing 222,  
   294  
 single-chain antibodies 205  
 single-molecule fluorescence 207  
 single-nucleotide variants (SNVs)  
   292  
 single-strand binding proteins 71



- size exclusion chromatography 109–110
- skin 39, 40, 55, 420
- sliding clamp 71
- small charged inorganic ions 34
- smaller antigen-binding molecules 348
- smaller, nonpolar molecules 33
- small fragments 335, 349
- small interfering RNAs (siRNA) 29, 297, 390
- small nuclear RNAs (snRNAs) 80
- small nucleolar RNAs (snoRNAs) 29, 82, 278
- small nucleotide polymorphisms (SNPs) 375
- small-RNA sequencing 293
- small tags 172
- small uncharged polar molecules 34
- Smith-Waterman algorithm 282, 292
- smooth ER 6, 41
- smooth out 280
- SMRT sequencing 157
- SNAP25 92
- SNARE proteins 92
- SNP analyses 67
- sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 107–108
- solvent contact surface 262
- somatic hypermutation 341, 342, 348
- somatic mutations 158, 324, 325, 329, 330
- Southern blotting 135, 137–139, 364
- Southern hybridization 27, 388
- SP6 promoters 162
- SP6 RNA polymerase 144
- spatial and temporal control of the expression 377
- specialized cloning bacteria 159
- specific adsorption 109
- specific antibodies 56, 112, 113, 125, 167, 205, 389
- specific optimized protocols (SOPs) 337
- specific signal peptide in the N-terminal 89
- spectral localization microscopy 203
- spectrally assigned localization microscopy (SALM) 203
- spectral precision distance microscopy (SPDM) 203
- spermatozoon 69
- S phase 72, 187
- spheroblasts 169
- sphingolipids 14
- sphingomyelin 14
- sphingosine 14, 241
- spindle apparatus 51, 69, 70
- spinning (Nipkow)-disk confocal microscopes 203
- spliceosome 80, 262
- splice sites 286
- spontaneous emission 209
- spotted/printed chip 287
- Src homology (SH) domains 261
- stability of an assay 303
- stability of transgenic plants 390
- stable inheritance patterns 390
- stable isotope labeling 123
- stable isotope labeling with labeled amino acids in cell culture (SILAC) 122
- stable transformation 379–381
- stably transfected cell clones 166–167
- stably transfected insect cell cultures 178
- staff departments 459
- standard elution method 112
- standard optical (bright-field) microscopy 201
- STAR algorithms 292
- starch 10, 376, 388
- start codon 81, 83, 164
- starter cultures 393
- statins 300
- stem cells 56, 57, 60, 68, 313, 354
- stem structures 29, 82
- stereoselectivity 395
- steroids 17, 37, 302
- sterols 5, 13, 16
- sticky ends 141–143, 161
- stimulated emission 209
- stimulated emission depletion microscopy (STED) 203
- stimulatory or inhibitory 353
- stock companies 424
- stock market 461
- stop codons 45, 75, 83, 164, 167, 286
- storage space 43, 282
- storage tissue 17
- storage vesicles 92
- strain collections 397
- Stramenopilata 3, 96, 97
- strand breaks 28
- strategic alliances 460, 461
- strategic collaboration 448
- strep tags 172, 349
- streptavidin fluorescent dye reagent 288
- striated muscle cells 50
- structural and functional genomics 63
- structural classification of proteins (SCOP) 279
- structural domains 22
- structural variants 292
- structure for deoxyribonucleic acid (DNA) 446
- structure-function relationship 399
- structured illumination (SI) 204
- submarine electrophoresis 134
- substituted bases 83
- substrates 22–24, 28, 111, 112, 180, 240, 248–250, 295, 298, 303
- specificity 23, 395, 398, 399
- sucrose 387, 406
- sugars 9, 34, 50, 113, 261, 295, 403
- suitable antibodies 313
- suitable peptide sequences 105
- sulfatases 42
- sulfated glucuronic acid 12
- sulfonamides 302
- sum of pairs function 282
- sum of squared residuals (SSR) 252, 253
- supernatant 106, 112, 114, 115, 129, 349
- supervised learning procedures 289
- support vector machines (SVMs) 289–290
- SureSelect 220
- surface antigen modification 56
- surface death receptors 61
- suspension cultures 178
- SV40 promoter 165
- SV40 replication origin 166
- SV40 termination site 166
- Swanson 449
- Swiss-Prot 278
- SYBR Green I 192
- symport 36
- synapsis 37, 70

- synaptobrevin 92  
 synchronized cell cultures of  
     *S. cerevisiae* 189  
 synonymous codons 81  
 syntaxin 92  
 synteny 68  
 synthesized by *in situ* synthesis 334  
 synthesized oligonucleotides 287  
 synthetic antibody gene library 342  
 synthetic biology 422  
 synthetic compounds 302  
 synthetic promoters 377  
 systems biology 404, 422
- t**
- TA cloning vectors 152  
 tag-*vs.* full-length sequencing 221  
 tag-specific antibody 113  
 tagged proteins 167  
 tail-biopsies 364  
 tailor-made biocatalysts 399  
 talampicillin 317  
 tandem repeat 66  
 tangible things 425  
 Taq DNA ligase 142  
 Taq polymerase 161  
 TaqMan<sup>®</sup> probes 332  
 TaqMan<sup>®</sup> system 333  
 target cells 37, 38, 313, 320, 372  
 targeted degradation of mRNA  
     301  
 targeted modification 306  
 targeted selection 159  
 target validation 300, 301  
 target vectors 163, 365  
 TA/UA cloning 161  
 tautomeric form 73  
 T7 bacteriophage 164  
 T-cell receptors (TCR) 355  
 T4 DNA ligase 142  
 Technology Platform, Market, and  
     Product Development 454  
 technology platforms 449  
 technology transfer or licensing  
     deals 460  
 telomerase 60, 68, 69, 87  
 telomere 28, 60, 66, 68, 69  
 telophase 69–71, 188  
 temperature optima 23  
 temperature- and pH-sensitive  
     liposomes 312  
 template DNA strand 75  
 term of patent 425  
 termination sequence 164
- tertiary protein structure 21  
 tertiary structures 19  
 testosterone 17  
 Tet system 166  
 Tet-off 166  
 Tet-on 166  
 tetanus toxins 55  
 tetracycline (Tc) 166  
 tetracycline-controlled  
     transactivator (tTA) 166  
 tetracycline resistance gene 159  
 tetracycline resistance operon of *E.*  
     coli 166  
 tetracycline-responsive elements  
     (TREs) 166  
 tetracycline system 368  
 tetraploid cells 366  
 The Cancer Genome Atlas Network  
     (TCGA) 227  
 therapeutic agents 295, 296, 300,  
     307  
 therapeutic antibodies 342  
 therapeutic applications 450  
 therapeutic proteins 393  
     *Thermus aquaticus* 137, 148  
 thiamine-inducible promoters 164,  
     177  
 third codon position 81  
 third generation sequencing  
     techniques 156  
 third harmonic generation (THG)  
     212  
 thromboxanes 14  
 thylakoids 47, 48, 89  
 thymidine 25, 28, 193, 231  
 Ti-plasmid 379, 380, 385  
 TIM22 complex 89  
 TIM23 complex 89  
 time-reversible evolution 284  
 tissue engineering products 419  
 tissue pieces 380  
 tobacco etch virus (TEV) 113, 175  
 tolerability 313  
 TOM complex 89  
 tophat algorithms 292  
 TO-PRO-3 192  
 TOPO TA Cloning\* system 161  
 topoisomerase 161  
 total market potential 460  
 toxin neutralization 350  
 T4 polynucleotide kinase (PNK)  
     144  
 T5 promoter 163  
 T7 promoter 162–163, 174, 180
- Trade Related Aspects of Intellectual  
     Property agreement (TRIPS)  
     428  
 trade sale 455  
 trade secrets 425, 426  
 trademarks 425  
 traditional biotechnology 413  
 traditional old economy industries  
     461  
 trait gene expression 389  
 transactivation systems 377  
 transcription 75  
 transcription activator-like effector  
     nucleases (TALEN) 361  
 transcription analysis 409  
 transcription factor (TF) 242, 295  
 transcription of cyclins 188  
 transcription of eukaryotic genes  
     77  
 transcription regulators 37  
 transcription terminators 164  
 transcription unit 72, 75, 78, 80,  
     363  
 transcription-activator-like effector  
     nucleases (TALENs) 274  
 transcriptional regulatory network  
     239  
 transcriptome sequencing  
     292–293  
 transcriptomics 77  
 transcripts per million (TPM) 292  
 transfection 177  
 transfection efficiency 165  
 transfer DNA (T-DNA) 379  
 transfer RNAs (tRNA) 29, 129, 221  
 transformed cells  
     consumer acceptance 385  
 transgenic founder mice 363  
 transgenic gene 361  
 transgenic line 363  
 transgenic mice  
     pronuclear injection 363–364  
     retroviral infection 362–363  
 transgenic plants 376, 387–388,  
     422  
 transient complexes 263  
 transient conformations 350  
 transient expression 381  
     of proteins 179  
 transient/stable expression of  
     recombinant protein 165  
 transient transformation 379  
 transition 73  
     probabilities 284

- translated coding sequences from  
EMBL (TrEMBL database)  
278
- translation of mRNA 163
- translation stop codons 174
- translation termination sites  
164
- translesion polymerases 73
- transmembrane areas 280
- transmembrane region 21
- transmission electron microscope  
(TEM) 197
- Transpath 279
- transport proteins 181
- transporters 35–37, 44, 54
- transposon yeast (TY) 165
- transversions 72, 73
- treatment of cancer 38
- tree of life 3, 83, 95, 96
- triacylglycerides 17
- trimeric G-proteins 38, 268
- trinucleotide repeats 220, 328
- trioses 9
- trisaccharide 9
- T4 RNA ligase 142
- T7 RNA polymerase 144
- Trp repressor homodimers 263
- TrueSeq DNA Exome 220
- trypsin 119, 264
- tryptone 176
- tryptophan operon 163
- t-SNARE receptors 92
- t-stochasticneighbor embedding  
(tSNE) 294
- tubercidin 410
- tubulin dimers 51
- tumor necrosis factor- $\alpha$  receptor  
300
- tumor stem cells 57, 354
- tumor therapy 315
- turgor regulation 43
- two parallel biosynthesis pathways  
408
- two-dimensional (2D) gel  
electrophoresis 108
- type I restriction endonucleases  
141
- type I restriction enzymes 141
- type II enzymes 141
- type II restriction endonucleases  
141
- type III enzymes 141
- type III restriction endonucleases  
141
- tyrosine kinases 38
- tyrosine-sulfated peptides 124
- u**
- ubiquitin 83
- Ullrich 447
- ULTRA-TURRAX<sup>®</sup> 106
- ultrafiltration 349
- ultraparallel sequencing 281
- bioethics of 294
- ChIP-seq 293
- epigenetic analysis 293–294
- mapping of 291–292
- single-cell analysis 294
- transcriptome sequencing  
292–293
- ultrasonic treatment 106
- UMAP methods 294
- underwriting banks 455
- unethical 428
- universal start codon 81
- universal triplet code 81
- unsaturated fatty acid 14
- unsupervised procedures 289
- untargeted way 311, 376
- untranslated regions 286
- upfront payment 460
- upstream inventions 431
- urea 20, 119, 125
- U.S. company Cetus 414
- utility patent 302
- UV radiation 72, 74
- v**
- vaccination 56, 383, 393,  
445
- vacuoles 42
- van der Waals forces 19, 263
- Vancomycin Resistant S. aureus*  
(VRSA) 55
- Vancomycin-resistant Enterococci*  
(VRE) 55
- variable number tandem repeats  
(VNTRs) 67
- variable regions 339
- vector(s) 159, 161
- vector DNA 159
- vector groups 162
- ventricular fibrillation 324
- venture capital 448
- very large nucleic acid molecules  
135
- vesicles 33
- budding of 92
- pinching off of 92
- uptake and secretion of 92
- vesicular transport 87
- V<sub>H</sub> domains 351
- Vibrio cholerae* 55, 297
- vinegar production 413
- viral diagnosis 326
- viral expression systems 165, 179,  
382
- for mammalian cells 167–168
- viral nucleic acids 56, 326
- Virchow, Rudolf 3
- virtual ligand screening 304–305
- virulence and pathogenicity 297
- virulence genes 55
- virus(es) 5, 55, 56
- virus shells 129
- virus-mediated gene deletion  
(Cre/lox) 370
- virus-mediated gene transfer  
369–370
- visual markers 383
- vitamin(s) 387
- vitamin B2 production 409
- vitamin D 16, 17, 37
- Viterbi algorithm 286
- void volume 110
- voltage-gatedcation channels 181
- voltage-gated channel 35
- v-SNARE proteins 92
- VybrantDyeCycle 192
- w**
- water solubility 129
- water-soluble organic solvents 109
- Watson–Crick pairing 269
- wave–particle dualism 209
- Western blotting 265, 389
- wheat germ extracts 113, 179
- white biotechnology 414, 423, 424
- whole blood 326
- whole-cell configuration 183, 184
- whole-exome sequencing (WES)  
292
- whole-genome bisulfite sequencing  
(WGBS) 223, 291
- of DNA 223, 291
- whole-genome sequencing (WGS)  
217–220, 223, 225, 231, 292,  
330
- wine production 393, 413
- work-around invention 432
- World Trade Organization (WTO)  
428

**X**

x-ray 21, 72, 105, 171, 262, 269,  
270, 278  
x-ray crystallography 266, 270  
xeroderma pigmentosum 74, 77  
xylose isomerase system 385

**Y**

yeast 106, 164, 175  
display 348  
proteins Hog1 and Fus3 266  
tRNA 30

vectors 164

yeast artificial chromosomes (YACs)  
160, 364  
yeast episomal plasmids (YEps)  
164  
yeast-integrating plasmids (YIps)  
164  
yeast-replicating plasmids (YRps)  
164  
yellow fluorescent protein (YFP)  
265, 266

**Z**

zebrafish (*Danio rerio*) 298  
Z factor 303  
zinc finger nuclease (ZFN) 361,  
378  
Zn affinity 349  
zygote 69, 70  
zygotene 70



